Page last updated: 2024-08-18

pyrroles and Diabetes Mellitus, Type 2

pyrroles has been researched along with Diabetes Mellitus, Type 2 in 314 studies

Research

Studies (314)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	7 (2.23)	18.2507
2000's	176 (56.05)	29.6817
2010's	116 (36.94)	24.3611
2020's	15 (4.78)	2.80

Authors

Authors	Studies
Honda, A; Ishii, I; Kamata, S; Machida, Y; Nemoto, A; Oyama, T; Satta, C; Terasawa, K; Uchii, K	1
El Medany, AMH; Ghazala, RA; Hammadi, SHM; Khalifa, HM; Zakaria Mohammed, HS	1
Ito, S; Kashihara, N; Nangaku, M; Okuda, Y; Sawanobori, T; Shikata, K; Sugimoto, K; Wada, T	1
Alarifi, S; Gautam, N; Mohseen, M; Pal, AK; Palanivel, H; Prabhu, SV; Saxena, M	1
Farooq Ur Rehman, RM; Khokhar, SA; Masood, S	1
Bako, HY; Ibrahim, MA; Ibrahim, S; Isah, MS	1
Bhansali, A; Bhansali, S; Hawkins, M; Jain, N; Kaur, S; Kurpad, AV; Rastogi, A; Sharma, A	1
Boeckmans, J; Buyl, K; De Kock, J; M Rodrigues, R; Natale, A; Rogiers, V; Rombaut, M; Vanhaecke, T	1
Bhatt, J; Dunbar, RL; Parmar, DV; Parmar, K; Rastogi, A; Thacker, HP	1
Dou, W; Guo, J; Hu, W; Huang, H; Li, M; Ma, Y; Xie, H; Zeng, S; Zhao, N; Zhao, X; Zhou, Q; Zhou, Y	1
Faldu, K; Krishnappa, M; Maroo, S; Mody, N; Parmar, D; Parmar, K; Patil, K; Shah, C; Trivedi, P	1
Nishiyama, A; Rahman, A; Wan, N	1
Homma, T; Igawa, Y; Yamada, M; Yamakawa, S; Yoshimura, M	1
Alajarín, R; de Pascual-Teresa, B; Di Geronimo, B; García-Marín, J; Griera, M; Mendicuti, F; Rodríguez-Puyol, D; Rodríguez-Puyol, M; Sánchez-Alonso, P; Vaquero, JJ	1
Chen, B; Liu, F; Liu, XP; Wang, DC; Xie, YM; Yan, TT	1
Ito, S; Kashihara, N; Nangaku, M; Okuda, Y; Sawanobori, T; Shikata, K; Wada, T	1
Rossing, P	1
Chhina, RS; Goyal, O; Goyal, P; Kaur, J; Nohria, S; Sharma, S; Sood, A	1
Bell, A; Clapper, W; Gunnet, J; Haug, P; Hua, H; Huebert, N; Jenkinson, C; Koudriakova, T; Leonard, J; Murray, WV; Suckow, A; Sui, Z; Wall, M; Wang, Y; Winters, MP; Yan, W	1
Bacos, K; Daneshpajooh, M; Eliasson, L; Ling, C	1
Balakumar, P; Mahadevan, N; Sambathkumar, R	1
Jaiswal, A; Kaul, U; Manjunath, K; Parmar, D; Parmar, K; Patil, KP; Shah, M	1
Hirayama, A; Hiro, T; Honye, J; Kodama, K; Komatsu, S; Li, Y; Nanto, S; Saito, S; Takayama, T; Takazawa, K; Ueda, Y; Yajima, J; Yamaguchi, O	1
Kennedy, RL; Malabu, UH; Vangaveti, V	1
Koh, KK	1
Boekholdt, SM; Pedersen, TR; Waters, DD	1
Filipiak, KJ; Mamcarz, A; Naruszewicz, M; Siebert, J; Sliż, D	1
Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR	1
Kang, HJ; Kim, HS; Lee, JH; Oh, BH; Park, YB; Sohn, DW	1
Farkouh, ME; Sethi, SS	1
Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J; Vides, H	1
Agrawal, R	1
Chen, JW; Chen, JY; Chien, KL; Hsia, CH; Hung, YR; Lin, HJ; Lin, LY; Liu, PY; Wu, TC; Yeh, HI	1
Bhansali, A; Jani, RH; Jariwala, G; Jha, P; Joshi, S; Mukhopadhyay, S; Pai, V	1
Eleftheriadou, I; Grigoropoulou, P; Katsilambros, N; Makrilakis, K; Margeli, A; Papassotiriou, I; Perrea, D; Tentolouris, N; Zoupas, C	1
Alkiş, N; Bal, O; Demirci, A; Durnali, A; Ekinci, AŞ; Eşbah, O; Oksüzoğlu, B	1
Bech, JN; Hansen, AB; Jensen, JM; Larsen, T; Mose, FH; Pedersen, EB	1
Louro, T; Matafome, P; Nunes, E; Seiça, RM; Sena, CM	1
Fotiadis, G; Kadoglou, NP; Kapelouzou, A; Liapis, CD; Sailer, N	1
Amato, AA; Puig, A; Scripko, PD	1
Aslam, M; Bhattacharya, SK; Galav, V; Jafri, AA; Madhu, SV	1
Deng, G; Deng, S; Ji, X; Jiang, H; Li, J; Li, Z; Liu, H; Su, M; Tang, C; Wang, J; Zhao, L	1
Atkin, SL; Kilpatrick, ES; Sathyapalan, T	4
Bao, W; Betteridge, DJ; Buchan, AP; Colhoun, H; DeMicco, DA; Durrington, PN; Fuller, JH; Hawa, MI; Hitman, GA; Leslie, RD; Neil, HA; Ola, T; Wun, CC	1
Chang, YH; Lee, YJ; Lin, KD; Shin, SJ	1
Goyal, A; Gupta, N; Gupta, YK; Singh, S; Tandon, N	1
Al-Azzam, SI; Alzayadeen, RN; Alzoubi, KH; Khabour, OF	1
Chang, TT; Chen, JS; Chen, JW; Huang, CC; Huang, PH; Leu, HB; Lin, LY; Lin, SJ; Wu, TC	1
Carlson, J	1
Chi, J; Guo, L; Jiang, L; Li, H; Li, M; Pan, Q; Sun, M; Wang, X; Wang, Y; Xian, T; Yu, D	1
Antunes, TT; Bruder-Nascimento, T; Callera, GE; He, Y; Montezano, AC; Nguyen Dinh Cat, A; Tostes, RC; Touyz, RM	1
Drechsler, C; Genser, B; Hengstschläger, M; Kaltenecker, CC; Kopecky, C; Krane, V; März, W; Säemann, MD; Wanner, C; Weichhart, T	1
Pwint, T; Tyrrell, HE	1
Chatterjee, S; Majumder, A; Ray, S	1
Chan, KA; Chou, HW; Lai, CL; Lai, MS	1
Betteridge, J; Bittner, VA; Fayyad, R; Hsue, PY; Laskey, R; Waters, DD; Wenger, NK	1
Joshi, SR	1
Karpov, RS; Konko, TIu; Koshel'skaia, OA; Kravchenko, ES; Suslova, TE; Vinnitskaia, IV	1
Luthra, A; Misra, A	2
Mudur, G	1
Jain, M; Jani, RH	1
Chandurkar, N; Pareek, A	1
Cai, X; Dai, Y; Fu, M; Huang, W; Li, Z; Pan, M; Qian, H; Shi, W; Su, X	1
Atsumi, T; Ishizu, A; Kusunoki, Y; Miyoshi, A; Miyoshi, H; Nakamura, A; Nakazawa, D; Shida, H; Tomaru, U; Yamada, M	1
Lam, S	1
Bhattacharjee, S; Das, N; Mandala, A; Mukherjee, B; Mukhopadhyay, S; Roy, SS	1
Chandra, N; Mateen, AA; Naidu, MU; Raju, YS; Usharani, P	1
Albalat-Galera, R; Berzosa-Sanchez, M; Ferrer-García, JC; Herrera-Ballester, A; Sanchez-Ballester, E	1
Bittner, VA; Breazna, A; Carmena, R; Deedwania, PC; Dobson, S; Kastelein, JP; Shepherd, J; Wenger, NK; Wilson, DJ; Zuckerman, AL	1
Auster, S; Betteridge, DJ; Colhoun, HM; Demicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Neil, HA; Newman, CB; Szarek, M	1
Baumann, M; Bierhaus, A; Bluemm, A; Dugi, KA; Heemann, U; Humpert, PM; Liu, D; Lutz, J; Nawroth, PP; Schuster, T; von Eynatten, M	1
Kékes, E	1
Drechsler, C; Krane, V; Lilienthal, J; März, W; Wanner, C; Winkler, K	2
de Teresa, E; Farsang, C; Gaw, A; Gensini, G; Langer, A; Leiter, LA; Martineau, P	1
Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Moedas, AR; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R	1
Betteridge, DJ; Charlton-Menys, V; Colhoun, H; DeMicco, DA; Durrington, PN; France, M; Fuller, J; Hitman, GA; Livingstone, SJ; Neil, HA; Newman, CB; Szarek, M	2
Balasubramanian, R; Baliga, VP; Bolmall, C; Kathale, A; Nagraj, LM; Nayak, UP; Periyandavar, I; Sharma, A; Varadharajan, S	1
Kadonosono, K; Takano, T; Tanaka, S; Terauchi, Y; Yamakawa, T	1
Farmer, A; Holman, RR; Neil, HA; Paul, S; Stratton, IM; Tucker, L	1
Amudha, K; Choy, AM; Lang, CC; Mustafa, MR	1
Channer, KS; Jones, TH; Kapoor, D; Stanworth, RD	1
Sniderman, A; Solhpour, A	1
Angermann, C; Bauersachs, J; Frantz, S; Heinrich, F; Krane, V; Lilienthal, J; Meesmann, M; Olschewski, M; Störk, S; Wanner, C	1
Dallinga-Thie, GM; Jansen, H; Kastelein, JJ; Sijbrands, EJ; van Hoek, M; van Tol, A; van Vark-van der Zee, LC	1
Blanco-Colio, LM; de Teresa, E; Dilaghi, B; Egido, J; Farsang, C; Gaw, A; Gensini, GF; Gori, AM; Langer, A; Leiter, LA; Martineau, P; Nozza, A; Rostagno, C	1
Glinkina, IV; Il'in, AV; Mel'nichenko, GA; Roĭtman, AP; Zilov, AV	1
Erem, C; Ersoz, HO; Hacihasanoglu, AB; Karti, SS; Ukinc, K	1
Dallinga-Thie, GM; Dullaart, RP; van Tol, A	1
Giraudeaux, V; Guillausseau, PJ; Kévorkian, JP; Laloi-Michelin, M; Meas, T; Peynet, J; Virally, M	1
Chowdhury, S; Mukherjee, S; Mukhopadhyay, P; Pandit, K	1
El-Remessy, AB; Elewa, HF; Ergul, A; Fagan, SC; Frye, RF; Johnson, MH; Kozak, A	1
Banga, JD; Dallinga-Thie, GM; Dullaart, RP; Huisman, MV; Kappelle, PJ; Sluiter, WJ; Zwang, L	1
Goldberg, RB; Guyton, JR; Jensen, E; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS	1
Betteridge, DJ; Charlton-Menys, V; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Neil, HA	1
Saito, Y; Yokote, K	1
Das, R; Jaydip, R; Mohan, V; Sudhakaran, C; Unnikrishnan, R	1
Betteridge, DJ; Chow, WS; Shiu, SW; Tam, HL; Tan, KC; Wong, Y	1
Boddu, SP; Du, M; Hua, Y; Kandadi, MR; Li, J; Rajanna, PK; Ren, J; Sreejayan, N; Unnikrishnan, MK	1
Altuntas, Y; Arinc, H; Bolayirli, M; Celebi, H; Dirican, A; Kanat, M; Karagoz, Y; Oguz, A; Sahin, S; Serin, E; Tunckale, A; Yildiz, O	1
Bi, S; Li, J; Li, YB; Liu, GD; Liu, XM; Su, Y; Sun, YM; Xu, Y	1
Dallinga-Thie, GM; Dullaart, RP; Kappelle, PJ	1
Ferdinand, KC; Flack, JM; Jamieson, MJ; Kursun, A; Saunders, E; Shi, H; Victor, R; Watson, K	1
Kuriyama, G; Mori, Y; Tajima, N; Tanaka, T	1
Antoniades, C; Charakida, M; Kamboli, AM; Koniari, K; Marinou, K; Miliou, A; Nikolopoulou, A; Noutsou, M; Papageorgiou, N; Siasos, G; Stefanadi, E; Stefanadis, C; Tousoulis, D	1
Bech, JN; Matthesen, SK; Paulsen, L; Pedersen, EB; Starklint, J	1
Annemans, L; Marbaix, S; Scheen, A; Van Gaal, L; Webb, K	1
Buchetti, B; Carnovale, A; Fallarino, M; Filetti, S; Gatti, A; Lenti, L; Lococo, E; Mandosi, E; Morano, S; Rossetti, M	1
Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K	1
Goldberg, RB; Guyton, JR; Mazzone, T; Polis, AB; Tershakovec, AM; Tipping, D; Tomassini, JE; Weinstock, RS	1
Berger, M; Krane, V; Lilienthal, J; Schambeck, C; Wanner, C; Winkler, K	1
Chan, KE; Hakim, RM; Lazarus, JM; Thadhani, R	1
Tuttle, KR	1
Harinarayan, CV; Kumar, R; Pola, P; Rajagopal, G; Reddy, AP; Sachan, A; Suchitra, MM; Suresh, V	1
Cariou, B; Costet, P; Guyomarc'h Delasalle, B; Hoffmann, MM; Konrad, T; Winkler, K	1
Abdel-Salam, Z; Adel, A; Nammas, W	1
Ceglarek, U; Farmer, A; Holman, RR; Neil, HA; Paul, S; Thiery, J	1
Bailey, C; Capps, N; Ramachandran, S; Saraf, S; Shetty, C	1
Bando, YK; Monji, A; Morimoto, Y; Murohara, T; Shigeta, T	1
Koh, KK; Quon, MJ; Sakuma, I	1
Charlton-Menys, V; Cruickshank, JK; Davies, RR; Dean, J; Durrington, PN; France, M; Gibson, JM; Gittins, M; Jinadev, P; Kalra, PA; Moorhouse, A; Prais, HR; Roberts, C; Rutter, MK; Wiles, PG	1
Antoniades, C; Koniari, K; Marinou, K; Miliou, A; Nikolopoulou, A; Noutsou, M; Papageorgiou, N; Stefanadi, E; Stefanadis, C; Tousoulis, D	1
Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R	1
Higa, M; Masuzaki, H; Shimabukuro, M; Shimabukuro, T; Tanaka, H; Yamakawa, K	1
Kadonosono, K; Kaneko, T; Kawaguchi, J; Morita, S; Shigematu, E; Terauchi, Y; Yamakawa, T	1
Allolio, B; Blouin, K; Drechsler, C; Fenske, W; Krane, V; Lilienthal, J; Wanner, C	1
Bancells, C; Benítez, S; Ordóñez-Llanos, J; Pérez, A; Sánchez-Quesada, JL; Wägner, AM	1
Arsenault, BJ; Barter, P; Breazna, A; Colhoun, H; DeMicco, DA; Ho, JE; Kastelein, JJ; Waters, DD; Wun, CC	1
Emanueli, C; Fortunato, O; Madeddu, P; Mangialardi, G; Monopoli, A; Ongini, E; Spinetti, G	1
Drechsler, C; Genser, B; Grammer, TB; Holdaas, H; Holme, I; Krane, V; März, W; Ritz, E; Scharnagl, H; Stojakovic, T; Wanner, C; Winkler, K	1
John, H; Kitas, GD; Toms, TE	1
Eeg-Olofsson, K; Eliasson, B; Gudbjörnsdóttir, S; Jonasson, JM; Miftaraj, M; Sundell, KA; Svensson, AM	1
Eren, MA; Koksal, M; Sabuncu, T; Turan, MN	1
Altafullah, I; Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, M; Ledbetter, LY; MacLeod, MJ; Messig, M; Samsa, GP; Scott, R; Sillesen, H; Welch, KM; Zivin, JA	1
Ahmed, D; Pillai, KK; Sharma, M	1
Fagan, SC; Guan, W; Kozak, A	1
Kadoglou, NP; Kapelouzou, A; Kostakis, A; Lampropoulos, S; Liapis, CD; Sailer, N; Vitta, I	1
Barter, PJ; Boekholdt, SM; Breazna, A; Kastelein, JJ; Rye, KA; Tardif, JC; Waters, DD	1
Budinski, D; Gosho, M; Gumprecht, J; Hounslow, N	1
Drechsler, C; Genser, B; Hoffmann, MM; März, W; Wanner, C	1
Arora, R; Dey, S; Kandhwal, K; Monif, T; Nazarudheen, S; Rao, S; Reyar, S; Singh, MK; Thudi, NR	1
Tanaka, M	1
Fraser, H; Goulder, MA; Hislop, C; Rosenson, RS	1
Ishii, H; Koyasu, M; Matsubara, T; Murohara, T; Shibata, R; Takemoto, K; Uemura, Y; Watarai, M; Yoshikawa, D	1
Schalkwijk, CG; Simsek, S; Wolffenbuttel, BH	1
Teramoto, T	1
Drechsler, C; Hoffmann, MM; Krane, V; Wanner, C; Winkler, K	1
Betteridge, DJ; Calle, RA; Caulfield, M; Charlton-Menys, V; Chatterjee, A; Colhoun, HM; DeMicco, DA; Deshmukh, HA; Durrington, PN; Ford, I; Fuller, JH; Hitman, GA; Hyde, C; Johnson, T; Jukema, JW; Livingstone, S; McKeigue, PM; Neil, A; Postmus, I; Poulter, N; Sever, P; Shields, DC; Stanton, AV; Trompet, S	1
Araki, A; Iimuro, S; Ito, H; Matsuyama, Y; Ohashi, Y; Sakurai, T; Shinozaki, T; Umegaki, H	1
Bragagnolo, JC; Catalano, H; Comignani, PD; Cornejo Pucci, E; Herrera, L; Igarzabal, C; Laffaye, N; Macchia, A; Mariani, JA; Nicolucci, A; Scazziota, AS; Tognoni, G	1
Hitman, GA	1
Scheen, AJ	1
Alavi, KH; Assadi, AR; Damavandi, M; Shafiee, K; Zangiabadi, N	1
El-Moselhy, MA; Heeba, GH; Mourad, AA; Taye, A	1
Cho, HJ; Kim, HS; Kim, SJ; Kwon, YW; Lee, HY; Lee, SW; Oh, BH; Park, YB; Youn, SW	1
Fromm, MF; Klatt, S; König, J	1
Dohadwala, MM; Farb, MG; Fetterman, JL; Frame, AA; Gokce, N; Hamburg, NM; Held, A; Holbrook, M; Kiani, S; Kluge, MA; Rosenzweig, J; Ruderman, N; Shenouda, SM; Tabit, CE; Vita, JA	1
Boekholdt, SM; Breazna, A; DeMicco, DA; Ho, JE; Kastelein, JJ; Messig, M; Pedersen, TR; Waters, DD	1
Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J	1
Fujimoto, M; He, P; Ishibashi, R; Ishikawa, T; Kawamura, H; Kobayashi, K; Okabe, E; Onishi, S; Takemoto, M; Yokote, K	1
Davies, RR; Durrington, P; Gibson, JM; Gittins, M; Hudson, JE; Narayanan, RP; Oliver, RL; Rutter, MK; Siddals, KW; White, A	1
Atkin, SL; Kilpatrick, ES; Sathyapalan, T; Shepherd, J	1
Velussi, M	1
Biswas, N; Brunzell, JD; Cohen, BR; Freed, MI; Kreider, MM; Marcovina, SM; Ratner, R	1
Huisman, MV; Kluft, C; Meinders, AE; Princen, HM; van de Ree, MA	1
Ikuta, H; Nagakura, T; Tanaka, I; Yamazaki, K; Yasuda, N	1
Berk-Planken, II; Bootsma, AH; Hoogerbrugge, N; Jansen, H; Stolk, RP	1
Calzoni, F; Dalla Nora, E; Fellin, R; Passaro, A; Solini, A; Zamboni, PF	1
Banga, JD; Dallinga-Thie, GM; Erkelens, DW; Sijmonsma, TP; Stolk, RP; van Tol, A; van Venrooij, FV	1
Charbonnel, B; Krempf, M; Laouenan, H; Magot, T; Marchini, JS; Ouguerram, K; Zaïr, Y	1
Daimon, M; Hirata, A; Igarashi, M; Kameda, W; Kato, T; Ohnuma, H; Oizumi, T; Saitoh, T; Sugiyama, K; Yamaguchi, H	1
Brandle, M; Davidson, MB; Herman, WH; Lorber, B; Schriger, DL	1
Betteridge, DJ; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Julier, K; Mackness, MI; Neil, HA; Soedamah-Muthu, SS; Thomason, MJ	1
Bonet, R; Jorba, O; Ordóñez-Llanos, J; Pérez, A; Wägner, AM	1
De Maat, MP; Huisman, MV; Kluft, C; Meinders, AE; Princen, HM; Van De Ree, MA	1
Akhmedzhanov, NM; Metel'kaya, VA; Oganov, RG; Raszzivin, VA; Vasiutina, EI	1
CarloTonolo, G; Carrozza, C; Lulli, P; Musumeci, S; Santini, SA; Zuppi, C	1
Gylling, H; Miettinen, TA	1
García-Idoate, G; Mora, C; Muros, M; Navarro, JF	1
Caselli, A; Economides, PA; Horton, ES; Khaodhiar, L; Tiani, E; Veves, A	1
Li, L; Renier, G; Sawamura, T	1
Bhansali, A; Gupta, A; Gupta, V; Thapar, S	1
Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C	1
Lawrence, JM; Reckless, JP; Reid, J; Stirling, C; Taylor, GJ	1
Berk-Planken, II; Bootsma, AH; Dallinga-Thie, GM; Jansen, H	1
Dugi, KA; Hamann, A; Nawroth, PP; Parhofer, KG; Schiekofer, S; Schneider, JG; Volkmer, JE; von Eynatten, M	1
Brier, RA; Briere, D; Brozinick, J; Burkholder, TP; Campbell, RM; Clay, MP; Clayton, J; Cunningham, B; Diefenbacher, C; Eessalu, TE; Engler, TA; Furness, K; Hawkins, E; Henry, JR; Iversen, PW; Li, Y; Lindstrom, TD; Malhotra, S; Marquart, AL; McLean, J; Mendel, D; Misener, E; O'Toole, JC; Owens, RA; Porter, WJ; Queener, S; Reel, JK; Vaughn, R; Wagner, JR	1
Betteridge, DJ; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Mackness, MI; Neil, HA; Thomason, MJ	1
Fan, Q; Huang, K; Li, R; Liu, X; Tu, L; Yao, H	1
Asmus, HG; Krämer, W; Krane, V; Kühn, KW; Kütemeyer, H; Mann, JF; März, W; Olschewski, M; Ritz, E; Ruf, G; Wanner, C	1
Aso, Y; Inukai, T; Sekine, K; Takanashi, K; Takebayashi, K; Yoshida, N; Yoshihara, K	1
Bagg, W; Braatvedt, GD; Davidson, J; Gamble, G; Reid, IR	1
Chan, WB; Chow, CC; Ko, GT; Ma, RC; Osaki, R; So, WY; Yeung, VT	1
Economides, PA; Horton, ES; Mantzoros, CS; Shetty, GK; Veves, A	1
Rollins, G	1
Bláha, V; Haas, T; Hyspler, R; Smahelová, A; Tichá, A; Zadák, Z	1
Alcaraz Tafalla, MS; Carrillo Alcaraz, A; Illán Gómez, F; Pascual Díaz, M	1
Jorba, O; Ordóñez-Llanos, J; Pérez, A; Wägner, AM	1
Bern, VH	1
Croom, KF; Plosker, GL	1
Endo, K; Ito, Y; Koide, N; Miyashita, Y; Otsuka, M; Oyama, T; Ozaki, H; Saiki, A; Shirai, K	1
Griebenow, R	1
Owen, OG	1
Bierhaus, A; Dugi, KA; Hadziselimovic, S; Hamann, A; Nawroth, PP; Schneider, JG; von Eynatten, M	1
Eisenbarth, GS	1
Lee, JD; Mikhailidis, DP; Morrissey, JR; Patel, V	1
Blanco, S; Egido, J; Gómez-Guerrero, C; López, D; Romero, R; Vaquero, M	1
Beevers, G; Caulfield, M; Collins, R; Dahlöf, B; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H	1
Assaloni, R; Ceriello, A; Da Ros, R; Esposito, K; Giugliano, D; Maier, A; Piconi, L; Quagliaro, L	1
Franken, AA; Vincent, HH; Wolffenbuttel, BH	1
Kakuta, H; Kihara, R; Shimano, H; Suzuki, M; Tada-Iida, K; Takahashi, A; Yamada, N; Yokoo, T	1
Jarernsiripornkul, N; Kiatchusakul, S; Ojongpian, S; Srinakarin, J; Tantikosoom, W; Thinkhamrop, B	1
Moreno Sánchez, D	1
Fantus, IG; Lewis, GF; Stavar, L; Szeto, L; Uffelman, K; Wang, CH; Wong, V	1
Hirose, T; Kawamori, R; Ohmura, C; Tanaka, Y; Watada, H	1
Bach-Ngohou, K; Bard, JM; Frénais, R; Krempf, M; Maugère, P; Ouguerram, K; Ripolles-Piquer, B; Zaïr, Y	1
Krane, V; Mann, JF; März, W; Olschewski, M; Ritz, E; Ruf, G; Wanner, C	1
Aso, Y; Inukai, T; Inukai, Y; Matsumoto, S; Matsutomo, R; Takebayashi, K; Wakabayashi, S	1
Emoto, M; Fujiwara, S; Fukumoto, S; Hatsuda, S; Kimoto, E; Koyama, H; Maeno, T; Nishizawa, Y; Shinohara, K; Shoji, T; Yokoyama, H	1
Tseng, KH	1
Fujinami, A; Fukui, M; Hasegawa, G; Ichida, Y; Nakamura, N; Nakano, K; Obayashi, H; Ohta, K; Ohta, M; Yoshikawa, T	1
Berne, C; Jørgensen, L; Sager, P; Siewert-Delle, A; Sorof, J	1
Langer, A	1
Robinson, JG	1
Jaber, BL; Madias, NE	1
Betteridge, DJ; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Neil, HA; Thomason, MJ	1
Hobbs, FD	1
Araki, A; Miyao, M; Sasamoto, K; Yamada, S; Yamanouchi, T; Yanagawa, T	1
Clearfield, M	1
Chu, CS; Lai, WT; Lee, KT; Lee, MY; Sheu, SH; Su, HM; Voon, WC	1
Ebisuno, M; Endo, K; Koide, N; Miyashita, Y; Ohira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Takeyoshi, M	1
Lynch, T	1
Charlton-Menys, V; Durrington, P	1
Dallinga-Thie, GM; Hattori, H; Rensen, PC; Sijbrands, EJ; van Tol, A	1
Ishibashi, S; Kusaka, I; Matsuoka, H; Nagasaka, S; Nakata, M; Yada, T	1
Barter, P; Breazna, A; Carmena, R; Deedwania, P; Fruchart, JC; Grundy, S; Haffner, S; Hsia, J; LaRosa, J; Shepherd, J; Waters, D	1
Kimura, M; Okamura, A; Takahashi, M; Takano, T; Yamakawa, T	1
Chu, CH; Chuang, MJ; Keng, HM; Lam, HC; Lee, JK; Lu, CC; Sun, CC; Tai, MH; Wang, MC; Wei, MC	1
Dallinga-Thie, GM; Hattori, H; Jansen, H; Sijbrands, EJ; van Tol, A; van Vark-van der Zee, LC	1
Geiss, HC; Huptas, S; Otto, C; Parhofer, KG	1
d'Emden, M; Knopp, RH; Pocock, SJ; Smilde, JG	1
Alonso Troncoso, I; Fernández de Bobadilla, J; López de Sa, E; Moreno Gómez, R; Rubio-Terrés, C; Soto Alvarez, J	1
Plummer, CJ	1
Cipriano, P; Di Marino, L; Gentile, A; Iovine, C; Lilli, S; Patti, L; Riccardi, G; Rivellese, AA	1
Krane, V; Wanner, C	1
Armani, A; Toth, PP	1
Antoniades, C; Charakida, M; Koniari, K; Kourtellaris, P; Marinou, K; Ntarladimas, I; Siasos, G; Stefanadis, C; Tousoulis, D; Vasiliadou, C	1
Beddhu, S; Cheung, AK; Kronenberg, F; Kwan, BC	1
Erkiliç, K; Koç, A; Mistik, S; Ozkiris, A	1
Andrýs, C; Bláha, M; Bláha, V; Hyspler, R; Knízek, J; Smahelová, A; Solichová, D; Zadák, Z	1
Betteridge, DJ; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Luo, D; Neil, HA	1
Gazi, IF; Mikhailidis, DP	1
Ferrer-García, JC; Herrera-Ballester, A; Martínez-Mir, I; Pérez-Silvestre, J	1
Edwards, P; Goldberg, RB; Guyton, JR; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS	1
Chen, Y; Kohno, M; Kosaka, H; Mizukawa, M; Ohmori, K; Shinomiya, K; Yoshida, J; Zeng, Y; Zhang, L	1
Imaizumi, T; Ishida, S; Jinnouchi, J; Jinnouchi, Y; Takeuchi, M; Yamagishi, S	1
Moulik, N; Patil, N; Rajadhyaksha, G; Save, V	1
Betteridge, DJ; Charlton-Menys, V; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; McGuire, A; Neil, HA; Raikou, M	1
Janíková, L; Stanková, B; Stopka, P; Tvrzická, E; Vareka, T; Vecka, M; Zahin, M; Zák, A; Zeman, M	1
Betteridge, DJ; Gibson, JM	1
McMahon, DE	1
Allen, C; Chung, N; Constance, C; Johnson-Levonas, AO; Lund, M; Massaad, R; McCrary Sisk, C; Westphal, S	1
Abe, M; Hirose, T; Kawamori, R; Mita, T; Nakayama, S; Ogihara, T; Shimizu, T; Uchino, H; Watada, H	1
Frost, RJ; Otto, B; Otto, C; Parhofer, KG; Pfeiffer, AF; Spranger, J; Vogeser, M	1
McClendon, KS; Riche, DM	1
Benatar, JR; Stewart, RA	1
Betteridge, DJ; Colhoun, H; Durrington, PN; Fuller, J; Hitman, GA; Livingstone, S; Neil, HA; Newman, C; Szarek, M	1
Arca, M	1
Betteridge, DJ; Gibson, JM; Sager, PT	1
Brunetti, ND; Casavecchia, GP; De Gennaro, L; Di Biase, M; Distaso, C; Maulucci, G; Pellegrino, PL	1
Lyseng-Williamson, KA; Plosker, GL	1
Bergeron, J; Couture, P; Deshaies, Y; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ	1
Caulin-Glaser, T; Falko, JM; Meis, SB; Moser, RJ	1
Dallinga-Thie, GM; Dunselman, PH; Jukema, JW; Liem, AH; Roeters van Lennep, HW; Zwinderman, AH	1
Bergeron, J; Couture, P; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ	1
Dupliakov, DV	1
Chu, CH; Chuang, MJ; Lam, HC; Lee, JK; Lu, CC; Sun, CC; Wang, MC; Wei, MC	1
Clarke, LD; Johnson, SJ; Liu, LZ; Ramsey, SD; Roberts, CS; Sullivan, SD	1
Akalin, A; Akcar, N; Sensoy, B; Temiz, G	1
Angel, I; Burcelin, R; Girard, J; Langer, SZ; Prouteau, M	1
Horie, K; Kurokawa, K; Maeda, K; Miyata, S; Miyata, T; Monnier, VM; Sakai, H; Sugiyama, S; van Ypersole de Strihou, C; Witztum, JL	1
Block, C; Ferguson, K; Fogarty, J; Haas, C; Hampel, N; Ni, Z; Polak, J; Razmjouei, K; Seftel, AD; Vaziri, ND; Wang, RZ	1
Aicher, TD; Balkan, B; Bell, PA; Brand, LJ; Cheon, SH; Deems, RO; Fell, JB; Fillers, WS; Fraser, JD; Gao, J; Kahle, GG; Knorr, DC; Leone, CL; Nadelson, J; Simpson, R; Smith, HC	1
Gänzer, H; Kirchmair, R; Patsch, JR; Sturm, W	1
Krane, V; März, W; Ritz, E; Ruf, G; Wanner, C	1
Barbagallo, M; Barbieri, M; Giordano, M; Paolisso, G; Petrella, G; Ragno, E; Varricchio, M	1
Cernigoi, AM; Merni, M; Tortul, C; Velussi, M	1
Aguilar-Salinas, CA; Alvarado Vega, A; Angélica Gómez-Díaz, R; Eduardo Romero-Nava, L; Gómez-Pérez, FJ; Guillén, LE; Gulías-Herrero, A; Meaney, E; Mendoza Pérez, E; Moguel, R; Novoa, G; Posadas-Romero, C; Salinas-Orozco, S; Vázquez-Chávez, C	1
Armitage, J; Betteridge, DJ; Colhoun, H	1
Amano, S; Horiuchi, S; Kaji, Y; Machinami, R; Nagai, R; Oka, T; Oshika, T	1
Frost, RJ; Geiss, HC; Otto, C; Parhofer, KG; Schwandt, P	1
Agrusta, M; Amodio, M; Corigliano, G; De Simone, G; Gaeta, I; Gentile, S; Guarino, G; Magliano, P; Oliviero, B; Salvatore, T; Sasso, CF; Torella, R; Turco, S	1
Goldner, D; Insull, W; Kafonek, S; Zieve, F	1
Desai, RC	1
Bairaktari, ET; Elisaf, MS; Liberopoulos, EN; Milionis, HJ	1
Geiss, HC; Otto, C; Parhofer, KG; Schwandt, P	1
Lemmens, PJ; Oranje, WA; Rondas-Colbers, GJ; Sels, JP; Wolffenbuttel, BH	1
Akanuma, Y; Kawakami, M; Ohashi, Y; Saito, Y; Tanaka, A; Yamada, N	1
Erkelens, DW	1
Ai, VH; Chow, WS; Lam, CH; Lam, KS; Tam, SC; Tan, KC	1
Adeli, K; Cheung, RC; Parris, W; Pontrelli, L	1
Betteridge, DJ; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Mackness, MI; Maton, SM; Neil, HA; Thomason, MJ	1
de Koning, EJ; Gaillard, CA; Honing, ML; Rabelink, TJ; Stroes, ES; van Etten, RW	1
Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA	1
Banga, JD; Bots, ML; Huisman, MV; Stolk, RP; van de Ree, MA; van Venrooij, FV	1

Reviews

23 review(s) available for pyrroles and Diabetes Mellitus, Type 2

Article	Year
Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. Cells, 2019, 12-21, Volume: 9, Issue:1 Topics: Chalcones; Diabetes Mellitus, Type 2; Drug Development; Fatty Liver; Humans; Hypoglycemic Agents; Inflammation; Liver; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Phenylpropionates; Pioglitazone; Propionates; Pyrroles	2019
Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease. Journal of human hypertension, 2021, Volume: 35, Issue:2 Topics: Animals; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Pyrroles; Receptors, Mineralocorticoid; Renal Insufficiency, Chronic; Spironolactone; Sulfones	2021
A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia. Current molecular pharmacology, 2019, Volume: 12, Issue:3 Topics: Diabetes Mellitus, Type 2; Disease Management; Dyslipidemias; Humans; Insulin Resistance; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles	2019
New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. Cardiovascular diabetology, 2019, 06-17, Volume: 18, Issue:1 Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; India; Lipids; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Signal Transduction; Time Factors; Treatment Outcome	2019
Changes in high-density-lipoprotein cholesterol upon statin treatment in type 2 diabetic patients: a meta-analysis. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2014, Volume: 24, Issue:10 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin; Triglycerides	2014
Saroglitazar for the treatment of dyslipidemia in diabetic patients. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:4 Topics: Animals; Atherosclerosis; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Glycated Hemoglobin; Humans; Lipids; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Risk Factors	2015
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk]. Orvosi hetilap, 2008, Sep-28, Volume: 149, Issue:39 Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors	2008
Differential metabolic effects of distinct statins. Atherosclerosis, 2011, Volume: 215, Issue:1 Topics: Adiponectin; Animals; Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mice; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2011
Rheumatoid arthritis: is it a coronary heart disease equivalent? Current opinion in cardiology, 2011, Volume: 26, Issue:4 Topics: Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Coronary Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hyperlipidemias; Pyrroles; Risk Factors	2011
Pitavastatin: clinical effects from the LIVES Study. Atherosclerosis. Supplements, 2011, Volume: 12, Issue:3 Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Diseases; Multicenter Studies as Topic; Muscular Diseases; Prospective Studies; Pyrroles; Quinolines; Risk; Simvastatin; Treatment Outcome; Triglycerides	2011
Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes. Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:6 Topics: Atorvastatin; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrazines; Pyrroles; Risk Assessment; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus. Drugs, 2005, Volume: 65, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Pyrroles	2005
[Medical management of primary nonalcoholic fatty liver disease]. Medicina clinica, 2005, Jun-18, Volume: 125, Issue:3 Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fatty Liver; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metabolic Syndrome; Metformin; Obesity; Orlistat; Prevalence; Pyrroles; Rosiglitazone; Thiazolidinediones; Troglitazone	2005
Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control. International journal of cardiology, 2006, Jun-16, Volume: 110, Issue:2 Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypolipidemic Agents; Models, Biological; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Triglycerides	2006
Apolipoproteins AI and B as therapeutic targets. Journal of internal medicine, 2006, Volume: 259, Issue:5 Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Lipoproteins; Lipoproteins, LDL; Postprandial Period; Pyrroles	2006
What's in the CARDS? Diabetic medicine : a journal of the British Diabetic Association, 2006, Volume: 23, Issue:7 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Risk Assessment; Smoking	2006
Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, Aug-01, Volume: 64, Issue:15 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles; Randomized Controlled Trials as Topic	2007
Is it time to stop treating dyslipidaemia with fibrates? The New Zealand medical journal, 2007, Sep-07, Volume: 120, Issue:1261 Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pyrroles; Randomized Controlled Trials as Topic	2007
Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. Drugs, 2007, Volume: 67 Suppl 1 Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Stroke	2007
Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events. PharmacoEconomics, 2007, Volume: 25, Issue:12 Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors	2007
Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia. Current diabetes reviews, 2005, Volume: 1, Issue:2 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Heptanoic Acids; Humans; Metabolic Syndrome; Niacin; Pyrroles; Triglycerides; United States	2005
[Clopidogrel and statins or once more on the danger of direct transfer of results of experimental studies in clinical practice]. Kardiologiia, 2008, Volume: 48, Issue:2 Topics: Atorvastatin; Clopidogrel; Coronary Thrombosis; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hypercholesterolemia; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine	2008
[Statins in diabetic hyperlipidemia]. Wiener medizinische Wochenschrift (1946), 1999, Volume: 149, Issue:5-6 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrroles; Risk Factors; Triglycerides	1999

Trials

158 trial(s) available for pyrroles and Diabetes Mellitus, Type 2

Article	Year
Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies. Journal of diabetes investigation, 2022, Volume: 13, Issue:7 Topics: Albumins; Albuminuria; Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Potassium; Pyrroles; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfones	2022
Comparison of efficiency between Rosuvastatin and Atorvastatin in reducing low-density lipoprotein (LDL-C) in patients with diabetes mellitus. JPMA. The Journal of the Pakistan Medical Association, 2022, Volume: 72, Issue:11 Topics: Atorvastatin; Cholesterol, LDL; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2022
Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial. Scientific reports, 2019, 12-12, Volume: 9, Issue:1 Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Endpoint Determination; Female; Glycated Hemoglobin; Humans; Hypertriglyceridemia; Insulin Resistance; Lipids; Male; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles	2019
Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study. Acta diabetologica, 2020, Volume: 57, Issue:7 Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; India; Male; Metformin; Middle Aged; Phenylpropionates; Placebos; Postprandial Period; PPAR alpha; PPAR gamma; Pyrroles; Triglycerides	2020
Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study). Cardiovascular diabetology, 2020, 06-19, Volume: 19, Issue:1 Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Lipids; Phenylpropionates; Pioglitazone; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome	2020
Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial. Clinical journal of the American Society of Nephrology : CJASN, 2020, 12-07, Volume: 15, Issue:12 Topics: Aged; Albuminuria; Biomarkers; Creatinine; Diabetes Mellitus, Type 2; Female; Humans; Japan; Kidney; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Pyrroles; Remission Induction; Risk Factors; Sulfones; Time Factors; Treatment Outcome	2020
Effects of ezetimibe/simvastatin 10/20 mg vs. atorvastatin 20 mg on apolipoprotein B/apolipoprotein A1 in Korean patients with type 2 diabetes mellitus: results of a randomized controlled trial. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2013, Volume: 13, Issue:5 Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Asian People; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Combinations; Dyslipidemias; Ezetimibe, Simvastatin Drug Combination; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Pyrroles; Republic of Korea; Simvastatin; Treatment Outcome	2013
Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects. Lipids in health and disease, 2013, Jul-16, Volume: 12 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Obesity; Peptide Fragments; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult	2013
Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study). PloS one, 2013, Volume: 8, Issue:10 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lipoproteins; Male; Middle Aged; Pyrroles; Quinolines; Risk Factors; Treatment Outcome; Triglycerides	2013
A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRES Diabetes technology & therapeutics, 2014, Volume: 16, Issue:2 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Patient Safety; Phenylpropionates; Prospective Studies; Pyrroles; Risk Reduction Behavior; Treatment Failure; Treatment Outcome; Triglycerides	2014
Effect of atorvastatin on baroreflex sensitivity in subjects with type 2 diabetes and dyslipidaemia. Diabetes & vascular disease research, 2014, Volume: 11, Issue:1 Topics: Aged; Atorvastatin; Baroreflex; Body Mass Index; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Diet, Fat-Restricted; Dyslipidemias; Female; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myalgia; Obesity; Patient Dropouts; Prospective Studies; Pyrroles; Risk Factors	2014
Effect of atorvastatin on renal NO availability and tubular function in patients with stage II-III chronic kidney disease and type 2 diabetes. Scandinavian journal of clinical and laboratory investigation, 2014, Volume: 74, Issue:1 Topics: Aged; Arginine Vasopressin; Atorvastatin; Atrial Natriuretic Factor; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules; Male; Middle Aged; Natriuretic Peptide, Brain; Nitric Oxide; omega-N-Methylarginine; Pulse Wave Analysis; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome; Vascular Stiffness; Vasopressins	2014
The impact of type 2 diabetes and atorvastatin treatment on serum levels of MMP-7 and MMP-8. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2014, Volume: 122, Issue:1 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Matrix Metalloproteinase 7; Matrix Metalloproteinase 8; Middle Aged; Pyrroles	2014
LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes. Diabetes care, 2014, Volume: 37, Issue:6 Topics: Adult; Age of Onset; Aged; Anticholesteremic Agents; Atorvastatin; Autoantibodies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glucose Intolerance; Glutamate Decarboxylase; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Middle Aged; Phenotype; Prevalence; Prospective Studies; Pyrroles; Risk Factors	2014
Effect of atorvastatin on pancreatic Beta-cell function and insulin resistance in type 2 diabetes mellitus patients: a randomized pilot study. Canadian journal of diabetes, 2014, Volume: 38, Issue:6 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Lipids; Male; Middle Aged; Pilot Projects; Pyrroles; Quality of Life	2014
Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study. Cardiovascular diabetology, 2014, Jul-16, Volume: 13 Topics: Aged; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelial Progenitor Cells; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrroles; Quinolines; Risk Factors; Treatment Outcome; Vascular Endothelial Growth Factor A	2014
Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis. Clinical journal of the American Society of Nephrology : CJASN, 2015, Feb-06, Volume: 10, Issue:2 Topics: Aged; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Germany; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipoproteins, HDL; Male; Middle Aged; Proportional Hazards Models; Pulmonary Surfactant-Associated Protein B; Pyrroles; Renal Dialysis; Risk Factors; Serum Amyloid A Protein; Time Factors; Treatment Outcome	2015
Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials. The American journal of cardiology, 2015, Feb-15, Volume: 115, Issue:4 Topics: Atorvastatin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Global Health; Heptanoic Acids; Humans; Incidence; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Sex Factors	2015
[Comparative Randomized Study of the Effects of Long-Term Therapy With Rosuvastatin and Combination of Atorvastatin and Ezetimibe on Carbohydrate Metabolism and Adipokines Levels in Patients With Coronary Artery Disease and Diabetes Mellitus]. Kardiologiia, 2015, Volume: 55, Issue:3 Topics: Adipokines; Anticholesteremic Agents; Atorvastatin; Azetidines; Blood Glucose; Carbohydrate Metabolism; Coronary Artery Disease; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome	2015
Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs in R&D, 2008, Volume: 9, Issue:4 Topics: Adrenergic beta-Agonists; Adult; Albuterol; Atorvastatin; Biomarkers; Blood Glucose; Cholesterol; Curcumin; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Oxidative Stress; Pyrroles; Triglycerides	2008
Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes. Journal of cardiovascular pharmacology and therapeutics, 2008, Volume: 13, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Feasibility Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Triglycerides	2008
Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clinic proceedings, 2008, Volume: 83, Issue:8 Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Risk; Treatment Outcome; United States	2008
The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes & vascular disease research, 2008, Volume: 5, Issue:3 Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastrointestinal Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ireland; Male; Middle Aged; Muscular Diseases; Practice Guidelines as Topic; Pyrroles; Time Factors; Treatment Outcome; United Kingdom	2008
Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes. Clinical endocrinology, 2009, Volume: 71, Issue:1 Topics: Adiponectin; Adult; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Protein Multimerization; Pyrroles	2009
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk]. Orvosi hetilap, 2008, Sep-28, Volume: 149, Issue:39 Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors	2008
Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney international, 2008, Volume: 74, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cause of Death; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Inflammation; Middle Aged; Placebos; Predictive Value of Tests; Pyrroles; Renal Dialysis; Survival Rate; Treatment Outcome; Young Adult	2008
How to reach LDL targets quickly in patients with diabetes or metabolic syndrome. The Journal of family practice, 2008, Volume: 57, Issue:10 Topics: Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome	2008
Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia, 2009, Volume: 52, Issue:2 Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins; Atorvastatin; Biomarkers; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Triglycerides	2009
Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients. Journal of the Indian Medical Association, 2008, Volume: 106, Issue:7 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Glycemic Index; Heptanoic Acids; Humans; Hypoglycemic Agents; India; Male; Metformin; Middle Aged; Pyrroles	2008
Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial. Diabetologia, 2009, Volume: 52, Issue:1 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Body Size; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Selection; Placebos; Pyrroles	2009
Short-term effect of atorvastatin on endothelial function in healthy offspring of parents with type 2 diabetes mellitus. Cardiovascular therapeutics, 2008,Winter, Volume: 26, Issue:4 Topics: Adolescent; Adult; Atorvastatin; Blood Flow Velocity; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Male; Pyrroles; Vasodilation; Young Adult	2008
Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clinical chemistry, 2009, Volume: 55, Issue:3 Topics: Adult; Aged; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles	2009
Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clinical journal of the American Society of Nephrology : CJASN, 2009, Volume: 4, Issue:2 Topics: Aged; Arrhythmias, Cardiac; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Electrocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Kaplan-Meier Estimate; Male; Middle Aged; Practice Guidelines as Topic; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome	2009
Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes. Current medical research and opinion, 2009, Volume: 25, Issue:1 Topics: Adiponectin; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Placebos; Pyrroles	2009
Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study. International journal of cardiology, 2010, Jul-23, Volume: 142, Issue:3 Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Risk Factors	2010
[Comparison of the effects of carbohydrate metabolism compensation and atorvastatin treatment on lipid metabolism and C-reactive protein in type 2 diabetes mellitus]. Terapevticheskii arkhiv, 2008, Volume: 80, Issue:12 Topics: Atorvastatin; C-Reactive Protein; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Male; Middle Aged; Pyrroles	2008
Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients. Endocrine, 2009, Volume: 35, Issue:3 Topics: Acute-Phase Proteins; Adult; Anticholesteremic Agents; Atorvastatin; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Ferritins; Fibrinogen; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Time Factors	2009
Plasma pre beta-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: Role of phospholipid transfer protein. Biochimica et biophysica acta, 2009, Volume: 1791, Issue:8 Topics: Atorvastatin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Heptanoic Acids; High-Density Lipoproteins, Pre-beta; Humans; Male; Middle Aged; Phospholipid Transfer Proteins; Pyrroles; Triglycerides	2009
Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile. European journal of internal medicine, 2009, Volume: 20, Issue:2 Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Triglycerides	2009
Atorvastatin improves arterial stiffness in normotensive normolipidaemic persons with type 2 diabetes. Journal of the Indian Medical Association, 2008, Volume: 106, Issue:11 Topics: Adult; Aged; Ankle; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Blood Flow Velocity; Blood Pressure; Body Mass Index; Brachial Artery; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pulsatile Flow; Pyrroles; Treatment Outcome	2008
Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:9 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Young Adult	2009
Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009, Volume: 54, Issue:5 Topics: Aged; Albuminuria; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles	2009
Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Journal of atherosclerosis and thrombosis, 2009, Volume: 16, Issue:3 Topics: Atherosclerosis; Atorvastatin; Diabetes Mellitus, Type 2; Glucose Intolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Quinolines; Treatment Outcome	2009
Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009, Volume: 54, Issue:5 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Inflammation; Male; Prospective Studies; Pyrroles; Renal Dialysis	2009
A multi-center, open label, crossover designed prospective study evaluating the effects of lipid lowering treatment on steroid synthesis in patients with Type 2 diabetes (MODEST Study). Journal of endocrinological investigation, 2009, Volume: 32, Issue:10 Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Cross-Over Studies; Dehydroepiandrosterone; Diabetes Mellitus, Type 2; Drug Administration Schedule; Estradiol; Ezetimibe; Female; Heptanoic Acids; Humans; Hydrocortisone; Luminescent Measurements; Male; Middle Aged; Prospective Studies; Pyrroles; Statistics, Nonparametric; Testosterone; Treatment Outcome	2009
Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets. Biochimica et biophysica acta, 2010, Volume: 1801, Issue:1 Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Pyrroles; Triglycerides	2010
Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes. Endocrine, 2009, Volume: 36, Issue:3 Topics: Aged; Atorvastatin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2009
Combined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus. International journal of cardiology, 2011, May-19, Volume: 149, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Pyrroles; Treatment Outcome; Tumor Necrosis Factor-alpha	2011
Acute effects of atorvastatin on glomerular filtration rate, tubular function, blood pressure, and vasoactive hormones in patients with type 2 diabetes. Journal of clinical pharmacology, 2010, Volume: 50, Issue:7 Topics: Adult; Aged; Atorvastatin; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules; Male; Middle Aged; Peptide Hormones; Pyrroles; Sodium	2010
Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia. Diabetes care, 2010, Volume: 33, Issue:5 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Black People; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Heptanoic Acids; Hispanic or Latino; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin	2010
Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes. Clinical journal of the American Society of Nephrology : CJASN, 2010, Volume: 5, Issue:5 Topics: Aged; Antibodies; Aspirin; Atorvastatin; Cause of Death; Chi-Square Distribution; Death, Sudden; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Kidney Diseases; Logistic Models; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Factor 4; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome	2010
Efficacy of low dose atorvastatin in diabetic dyslipidaemia. Journal of the Indian Medical Association, 2009, Volume: 107, Issue:11 Topics: Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome	2009
Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis, 2010, Volume: 212, Issue:1 Topics: Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; France; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Time Factors; Treatment Outcome; Triglycerides; Up-Regulation	2010
Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with type 2 diabetes. Diabetes care, 2010, Volume: 33, Issue:9 Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Pyrroles; Simvastatin	2010
Low-dose statin therapy improves endothelial function in type 2 diabetic patients with normal serum total cholesterol: a randomized placebo-controlled study. Journal of clinical hypertension (Greenwich, Conn.), 2010, Volume: 12, Issue:10 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Brachial Artery; Cholesterol; Diabetes Mellitus, Type 2; Endothelium, Vascular; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Placebos; Pyrroles; Statistics, Nonparametric; Time Factors	2010
Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial. Atherosclerosis, 2010, Volume: 213, Issue:2 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Docosahexaenoic Acids; Double-Blind Method; Drug Combinations; Eicosapentaenoic Acid; Heptanoic Acids; Humans; Lanosterol; Phytosterols; Pyrroles; Triglycerides	2010
Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1). Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:1 Topics: Albuminuria; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome; United Kingdom	2011
Impact of 6 weeks of treatment with low-dose metformin and atorvastatin on glucose-induced changes of endothelial function in adults with newly diagnosed type 2 diabetes mellitus: A single-blind study. Clinical therapeutics, 2010, Volume: 32, Issue:10 Topics: Atherosclerosis; Atorvastatin; Blood Flow Velocity; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Female; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Plethysmography; Pyrroles; Single-Blind Method; Treatment Outcome; Vasodilation	2010
Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus. Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:7 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome	2011
Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. Journal of the American Society of Nephrology : JASN, 2011, Volume: 22, Issue:4 Topics: Aged; Atorvastatin; Biomarkers; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glycopeptides; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Predictive Value of Tests; Pyrroles; Regression Analysis; Risk Factors; Stroke; Treatment Outcome	2011
Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study. Diabetes research and clinical practice, 2011, Volume: 93, Issue:1 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Atorvastatin; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fibric Acids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Phospholipases A2; Phospholipases A2, Secretory; Pyrroles	2011
Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. Journal of the American College of Cardiology, 2011, Apr-05, Volume: 57, Issue:14 Topics: Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Female; Forecasting; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Pyrroles; Risk Factors	2011
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical journal of the American Society of Nephrology : CJASN, 2011, Volume: 6, Issue:6 Topics: Aged; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Dyslipidemias; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome	2011
The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients. European journal of internal medicine, 2011, Volume: 22, Issue:3 Topics: Adolescent; Adult; Aged; Antioxidants; Atorvastatin; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Oxidative Stress; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Young Adult	2011
Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Archives of neurology, 2011, Volume: 68, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Physiological Phenomena; Cholesterol; Confidence Intervals; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Lipoproteins, HDL; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Factors; Stroke; Triglycerides; Young Adult	2011
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation, 2011, Aug-02, Volume: 124, Issue:5 Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glycated Hemoglobin; Heptanoic Acids; Homeostasis; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines	2011
Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:11 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome; Young Adult	2011
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study. Atherosclerosis, 2011, Volume: 219, Issue:2 Topics: Aged; Analysis of Variance; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Female; Genetic Predisposition to Disease; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Logistic Models; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Treatment Outcome	2011
Pharmacokinetics of a fixed-dose combination of atorvastatin and metformin extended release versus concurrent administration of individual formulations: a randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivale Clinical drug investigation, 2011, Dec-01, Volume: 31, Issue:12 Topics: Adult; Asian People; Atorvastatin; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Combinations; Electrocardiography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrroles; Therapeutic Equivalency; Vital Signs; Young Adult	2011
Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome. Cardiovascular drugs and therapy, 2011, Volume: 25, Issue:6 Topics: Acetates; Acute Coronary Syndrome; Anti-Inflammatory Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Group II Phospholipases A2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-6; Keto Acids; Male; Middle Aged; Pyrroles; Treatment Outcome	2011
Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. Journal of cardiology, 2012, Volume: 59, Issue:1 Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Glucose Intolerance; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Malondialdehyde; Oxidation-Reduction; Prospective Studies; Pyrroles	2012
Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes---the CORALL study. Diabetic medicine : a journal of the British Diabetic Association, 2012, Volume: 29, Issue:5 Topics: Atorvastatin; Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Fasting; Female; Fluorobenzenes; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Netherlands; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2012
Lipoprotein-associated phospholipase A2 and outcome in patients with type 2 diabetes on haemodialysis. European journal of clinical investigation, 2012, Volume: 42, Issue:7 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Area Under Curve; Atorvastatin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Predictive Value of Tests; Pyrroles; Renal Dialysis; Risk Factors	2012
Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial. PloS one, 2012, Volume: 7, Issue:3 Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Thrombin	2012
Atorvastatin treatment improves diabetic polyneuropathy electrophysiological changes in non-insulin dependent diabetic patients: a double blind, randomized clinical trial. Minerva endocrinologica, 2012, Volume: 37, Issue:2 Topics: Animals; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Electrophysiology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neural Conduction; Pyrroles; Rats; Tibial Nerve	2012
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. Journal of the American College of Cardiology, 2013, Jan-15, Volume: 61, Issue:2 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Simvastatin; Stroke	2013
The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:6 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Blood Glucose; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Fasting; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2013
Atorvastatin administration is associated with dose-related changes in IGF bioavailability. European journal of endocrinology, 2013, Volume: 168, Issue:4 Topics: Aged; Atorvastatin; Biological Availability; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Male; Middle Aged; Pyrroles	2013
Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. The American journal of cardiology, 2002, Nov-01, Volume: 90, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; North America; Pyrroles; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Time Factors; Treatment Outcome	2002
Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis, 2003, Volume: 166, Issue:1 Topics: Aged; Atorvastatin; Body Mass Index; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Middle Aged; Pyrroles; Treatment Outcome	2003
Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant. Diabetes care, 2003, Volume: 26, Issue:2 Topics: Aged; Alleles; Atorvastatin; Black People; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Genetic Variation; Heptanoic Acids; Heterozygote; Humans; Hyperlipidemias; Lipase; Liver; Male; Middle Aged; Polymorphism, Genetic; Promoter Regions, Genetic; Pyrroles; Sex Characteristics; White People	2003
Atorvastatin improves metabolic control and endothelial function in type 2 diabetic patients: a placebo-controlled study. Journal of endocrinological investigation, 2003, Volume: 26, Issue:1 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cadherins; Cholesterol, LDL; Diabetes Mellitus, Type 2; E-Selectin; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Placebos; Pyrroles; Vascular Cell Adhesion Molecule-1	2003
Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes care, 2003, Volume: 26, Issue:4 Topics: Aged; Atorvastatin; Base Sequence; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Diabetes Mellitus, Type 2; DNA Primers; Double-Blind Method; Female; Genotype; Glycated Hemoglobin; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Selection; Placebos; Polymorphism, Genetic; Pyrroles; Restriction Mapping; Triglycerides	2003
The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis, 2003, Volume: 167, Issue:2 Topics: Aged; Atorvastatin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Magnetic Resonance Spectroscopy; Male; Middle Aged; Myocardial Ischemia; Patient Compliance; Probability; Pyrroles; Reference Values; Risk Assessment; Treatment Outcome	2003
Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:7 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Gemfibrozil; Heptanoic Acids; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Treatment Outcome	2003
Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus. Journal of thrombosis and haemostasis : JTH, 2003, Volume: 1, Issue:8 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Factor VIIIa; Female; Fibrinogen; Hemostatics; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Placebos; Pyrroles; Risk Factors; Time Factors; Tissue Plasminogen Activator; von Willebrand Factor	2003
Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia. Journal of atherosclerosis and thrombosis, 2003, Volume: 10, Issue:3 Topics: Adrenal Cortex Hormones; Adrenal Glands; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Female; Gonadal Steroid Hormones; Gonads; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Severity of Illness Index	2003
The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. The Journal of clinical endocrinology and metabolism, 2004, Volume: 89, Issue:2 Topics: Adult; Atorvastatin; Biomarkers; Brachial Artery; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Microcirculation; Middle Aged; Nitroglycerin; Pyrroles; Regional Blood Flow; Risk Factors; Skin; Vasodilation; Vasodilator Agents	2004
Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. American journal of ophthalmology, 2004, Volume: 137, Issue:4 Topics: Administration, Oral; Atorvastatin; Chemotherapy, Adjuvant; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Exudates and Transudates; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Laser Coagulation; Lipoproteins, LDL; Macular Edema; Male; Middle Aged; Prospective Studies; Pyrroles; Triglycerides; Visual Acuity	2004
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. American heart journal, 2004, Volume: 147, Issue:4 Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides	2004
The effect of high dose atorvastatin therapy on lipids and lipoprotein subfractions in overweight patients with type 2 diabetes. Atherosclerosis, 2004, Volume: 174, Issue:1 Topics: Aged; Aged, 80 and over; Analysis of Variance; Apolipoproteins B; Atorvastatin; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Lipid Metabolism; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Obesity; Pyrroles; Reference Values; Treatment Outcome	2004
Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides. Diabetes care, 2004, Volume: 27, Issue:6 Topics: Angiotensin-Converting Enzyme Inhibitors; Apolipoprotein C-III; Apolipoproteins B; Apolipoproteins C; Atorvastatin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypertriglyceridemia; Lipoproteins, HDL; Male; Middle Aged; Pyrroles; Triglycerides	2004
Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. Atherosclerosis, 2004, Volume: 175, Issue:2 Topics: Aged; Atorvastatin; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Lipoprotein Lipase; Male; Middle Aged; Pyrroles; Triglycerides	2004
Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2004, Volume: 21, Issue:8 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Triglycerides	2004
Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney & blood pressure research, 2004, Volume: 27, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Renal; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Renal Dialysis	2004
The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetes. Bone, 2004, Volume: 35, Issue:3 Topics: Atorvastatin; Biomarkers; Bone Remodeling; Confidence Intervals; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Osteocalcin; Pyrroles	2004
A comparative study of atorvastatin and simvastatin as monotherapy for mixed hyperlipidaemia in Type 2 diabetic patients. Diabetes research and clinical practice, 2004, Volume: 66, Issue:1 Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides	2004
Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes care, 2004, Volume: 27, Issue:10 Topics: Adiponectin; Adult; Age Distribution; Aged; Atorvastatin; Biomarkers; Body Mass Index; C-Reactive Protein; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Hormones, Ectopic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Inflammation Mediators; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Prediabetic State; Predictive Value of Tests; Probability; Prognosis; Pyrroles; Reference Values; Resistin; Risk Assessment; Sex Distribution; Vascular Resistance	2004
Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes. Metabolism: clinical and experimental, 2004, Volume: 53, Issue:11 Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides	2004
Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia. Journal of atherosclerosis and thrombosis, 2004, Volume: 11, Issue:6 Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein Lipase; Middle Aged; Pravastatin; Pyrroles	2004
The collaborative atorvastatin diabetes study: preliminary results. International journal of clinical practice, 2005, Volume: 59, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Prospective Studies; Pyrroles	2005
Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes. Diabetes care, 2005, Volume: 28, Issue:3 Topics: Adiponectin; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Hormones, Ectopic; Humans; Intercellular Signaling Peptides and Proteins; Leptin; Male; Placebos; Pyrroles; Resistin	2005
Statin treatment of patients with diabetes. Current diabetes reports, 2005, Volume: 5, Issue:2 Topics: Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles	2005
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes care, 2005, Volume: 28, Issue:5 Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke	2005
Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation, 2005, May-17, Volume: 111, Issue:19 Topics: Anticholesteremic Agents; Atorvastatin; Biphenyl Compounds; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperglycemia; Hypertriglyceridemia; Inflammation; Irbesartan; Male; Middle Aged; Oxidative Stress; Postprandial Period; Pyrroles; Tetrazoles; Treatment Outcome	2005
Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study. Journal of internal medicine, 2005, Volume: 257, Issue:6 Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides	2005
Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2005, Volume: 88, Issue:3 Topics: Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Outpatients; Pyrroles; Vascular Diseases	2005
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. The New England journal of medicine, 2005, Jul-21, Volume: 353, Issue:3 Topics: Aged; Atorvastatin; Cerebrovascular Disorders; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Renal Dialysis; Stroke	2005
The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia. Metabolism: clinical and experimental, 2005, Volume: 54, Issue:9 Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Chemokine CCL2; Diabetes Mellitus, Type 2; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles	2005
Effect of atorvastatin on in vitro expression of resistin in adipocytes and monocytes/macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes. Pharmacology, 2006, Volume: 76, Issue:1 Topics: 3T3-L1 Cells; Adipocytes; Animals; Atorvastatin; Cells, Cultured; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Male; Mice; Middle Aged; Monocytes; Pyrroles; Resistin; RNA, Messenger	2006
Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diabetes research and clinical practice, 2006, Volume: 72, Issue:1 Topics: Aged; Albuminuria; Atorvastatin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Function Tests; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides	2006
Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia, 2005, Volume: 48, Issue:12 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Proportional Hazards Models; Pyrroles; Risk Factors; Time Factors; Treatment Outcome	2005
Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients. Metabolism: clinical and experimental, 2006, Volume: 55, Issue:1 Topics: Adult; Atorvastatin; Biomarkers; Blood Pressure; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Japan; Liver; Liver Function Tests; Male; Middle Aged; Pyrroles	2006
Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. The American journal of cardiology, 2006, Mar-01, Volume: 97, Issue:5 Topics: Adiponectin; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; CD40 Ligand; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Matrix Metalloproteinase 9; Middle Aged; Pyrroles; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Triglycerides; Vasodilator Agents	2006
Probucol and atorvastatin decrease urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia. Journal of atherosclerosis and thrombosis, 2006, Volume: 13, Issue:1 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Anticholesteremic Agents; Antioxidants; Atorvastatin; Biomarkers; Deoxyguanosine; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Oxidative Stress; Probucol; Pyrroles; Treatment Outcome	2006
Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein E? Diabetes, 2006, Volume: 55, Issue:5 Topics: Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins E; Atorvastatin; Cholesterol; Diabetes Mellitus, Type 2; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Phospholipid Transfer Proteins; Placebos; Pyrroles	2006
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes care, 2006, Volume: 29, Issue:6 Topics: Aged; Atorvastatin; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Triglycerides	2006
The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia. Experimental biology and medicine (Maywood, N.J.), 2006, Volume: 231, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyslipidemias; Endothelin-1; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Pyrroles	2006
Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Diabetologia, 2006, Volume: 49, Issue:7 Topics: Aged; Apolipoprotein A-V; Apolipoprotein C-III; Apolipoproteins A; Apolipoproteins E; Atorvastatin; Diabetes Complications; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Genetic Variation; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Placebos; Pyrroles; Triglycerides	2006
Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome. The American journal of cardiology, 2006, Jul-01, Volume: 98, Issue:1 Topics: Adult; Atorvastatin; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Pyrroles; Treatment Outcome	2006
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes care, 2006, Volume: 29, Issue:7 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Risk Assessment; Treatment Outcome	2006
Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia. European journal of clinical investigation, 2006, Volume: 36, Issue:8 Topics: Anticholesteremic Agents; Area Under Curve; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, VLDL; Male; Middle Aged; Postprandial Period; Pyrroles; Treatment Outcome; Triglycerides	2006
Lessons learnt from the 4D trial. Nephrologie & therapeutique, 2006, Volume: 2, Issue:1 Topics: Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Placebos; Pyrroles; Renal Dialysis	2006
The CARDS trial: diabetic patients dealt a winning hand. Current atherosclerosis reports, 2006, Volume: 8, Issue:5 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Prospective Studies; Pyrroles; Risk Factors; Treatment Outcome	2006
Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmentrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus. Heart (British Cardiac Society), 2007, Volume: 93, Issue:2 Topics: Anti-Inflammatory Agents; Antioxidants; Arginine; Ascorbic Acid; Atorvastatin; Cytokines; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hyperemia; Male; Middle Aged; Pyrroles; Regional Blood Flow; Single-Blind Method; Vitamins	2007
Effect of atorvastatin on ocular blood flow velocities in patients with diabetic retinopathy. The British journal of ophthalmology, 2007, Volume: 91, Issue:1 Topics: Atorvastatin; Blood Flow Velocity; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Double-Blind Method; Eye; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Ophthalmic Artery; Pyrroles; Retinal Artery; Triglycerides	2007
Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes care, 2006, Volume: 29, Issue:11 Topics: Adult; Age Distribution; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Risk Reduction Behavior; Stroke	2006
Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia. Acta diabetologica, 2006, Volume: 43, Issue:3 Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Administration Schedule; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Spain	2006
Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clinic proceedings, 2006, Volume: 81, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin	2006
Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clinical and experimental medicine, 2006, Volume: 6, Issue:4 Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Female; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Matched-Pair Analysis; Pyrroles	2006
Effect of atorvastatin on type 2 diabetic dyslipidemia. Journal of cardiovascular pharmacology and therapeutics, 2006, Volume: 11, Issue:4 Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein B-100; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glutathione; Glutathione Peroxidase; Glutathione Transferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Pyrroles; Superoxide Dismutase; Time Factors; Treatment Outcome; Triglycerides	2006
[Oxidation stress, insulin resistance and endothelial dysfunction during the treatment of hyperlipidaemia]. Casopis lekaru ceskych, 2006, Volume: 145, Issue:12 Topics: Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Endothelium, Vascular; Fatty Acids, Omega-3; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Oxidative Stress; Pyrroles; Simvastatin	2006
Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2007, Volume: 24, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides	2007
Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Body Mass Index; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides	2007
Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia. Endocrine journal, 2007, Volume: 54, Issue:3 Topics: Atorvastatin; Cross-Over Studies; Diabetes Mellitus, Type 2; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Humans; Hypercholesterolemia; Insulin-Secreting Cells; Japan; Patient Compliance; Pravastatin; Pyrroles	2007
Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta diabetologica, 2007, Volume: 44, Issue:2 Topics: Adiponectin; Aged; Atorvastatin; Body Mass Index; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fenofibrate; Ghrelin; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Peptide Hormones; Pyrroles; Resistin	2007
Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetic medicine : a journal of the British Diabetic Association, 2007, Volume: 24, Issue:12 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Pyrroles; Risk Factors; Stroke	2007
Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). The American journal of cardiology, 2007, Oct-15, Volume: 100, Issue:8 Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; England; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North Carolina; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2007
Improvement in endothelium dysfunction in diabetics treated with statins: a randomized comparison of atorvastatin 20 mg versus rosuvastatin 10 mg. Journal of interventional cardiology, 2007, Volume: 20, Issue:6 Topics: Aged; Atorvastatin; C-Reactive Protein; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Regional Blood Flow; Rosuvastatin Calcium; Sulfonamides; Vasodilation	2007
Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism: clinical and experimental, 2008, Volume: 57, Issue:2 Topics: Anticholesteremic Agents; Apolipoprotein B-100; Apolipoprotein B-48; Atorvastatin; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Fenofibrate; Heptanoic Acids; Humans; Hypertriglyceridemia; Kinetics; Leucine; Male; Middle Aged; Pyrroles; Triglycerides	2008
The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Current medical research and opinion, 2008, Volume: 24, Issue:3 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome	2008
Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism: clinical and experimental, 2008, Volume: 57, Issue:3 Topics: Atorvastatin; Biomarkers; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Inflammation; Lipids; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pyrroles	2008
Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic Type 2 diabetes. Journal of endocrinological investigation, 2008, Volume: 31, Issue:1 Topics: Adiponectin; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hyperlipidemias; Insulin Resistance; Leptin; Male; Middle Aged; Pyrroles	2008
Flexible initial dosing of atorvastatin based upon initial low-density lipoprotein cholesterol levels in type 2 diabetic patients. The Korean journal of internal medicine, 2008, Volume: 23, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Brachial Artery; Cholesterol, LDL; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrroles; Regional Blood Flow; Time Factors; Treatment Outcome	2008
Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis, 2000, Volume: 150, Issue:1 Topics: Aged; Atorvastatin; Calorimetry, Indirect; Carbon Dioxide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Oxygen Consumption; Pyrroles; Simvastatin; Single-Blind Method; Triglycerides	2000
Atorvastatin for the management of Type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience. Diabetes, nutrition & metabolism, 1999, Volume: 12, Issue:6 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Male; Middle Aged; Pyrroles; Triglycerides	1999
Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study. Atherosclerosis, 2000, Volume: 152, Issue:2 Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles	2000
Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. The American journal of cardiology, 2001, Jan-01, Volume: 87, Issue:1 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fenofibrate; Hemorheology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Prospective Studies; Pyrroles; Statistics, Nonparametric	2001
Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. Diabetes, obesity & metabolism, 2000, Volume: 2, Issue:6 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Lovastatin; Male; Middle Aged; Placebos; Pravastatin; Pyrroles; Simvastatin; Triglycerides	2000
Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators. The American journal of cardiology, 2001, Mar-01, Volume: 87, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome	2001
The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes care, 2001, Volume: 24, Issue:8 Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diabetic Retinopathy; Dose-Response Relationship, Drug; Double-Blind Method; Fatty Acids, Nonesterified; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipoprotein Lipase; Lipoproteins; Male; Middle Aged; Placebos; Pyrroles; Time Factors; Triglycerides	2001
Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients. Clinica chimica acta; international journal of clinical chemistry, 2001, Sep-25, Volume: 311, Issue:2 Topics: Aged; Anticholesteremic Agents; Antioxidants; Atorvastatin; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Oxidation-Reduction; Pyrroles; Ubiquinone; Vitamin E	2001
A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia. Clinica chimica acta; international journal of clinical chemistry, 2001, Volume: 312, Issue:1-2 Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Blood Glucose; Cholesterol; Deoxyglucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fructosamine; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles	2001
Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. The Journal of clinical endocrinology and metabolism, 2002, Volume: 87, Issue:2 Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Reference Values; Triglycerides; Ultrasonography; Vasodilation	2002
Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism: clinical and experimental, 2002, Volume: 51, Issue:3 Topics: Apolipoproteins B; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin Resistance; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Particle Size; Peptide Fragments; Pyrroles	2002
Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2002, Volume: 19, Issue:3 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Lipids; Lipoproteins; Middle Aged; Patient Selection; Placebos; Pyrroles; Research Design	2002
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes care, 2002, Volume: 25, Issue:7 Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Lipoprotein(a); Lipoproteins, HDL; Male; Middle Aged; Pyrroles; Triglycerides	2002
Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes care, 2002, Volume: 25, Issue:7 Topics: Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Lipids; Male; Middle Aged; Placebos; Pyrroles; Smoking; Vasodilation	2002

Other Studies

134 other study(ies) available for pyrroles and Diabetes Mellitus, Type 2

Article	Year
Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist. Biological & pharmaceutical bulletin, 2021, Volume: 44, Issue:9 Topics: Binding Sites; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypolipidemic Agents; Lipid Metabolism; Non-alcoholic Fatty Liver Disease; Phenylpropionates; PPAR alpha; PPAR gamma; Protein Domains; Pyrroles; Recombinant Proteins	2021
The vascular impact of dapagliflozin, liraglutide, and atorvastatin alone or in combinations in type 2 diabetic rat model. Fundamental & clinical pharmacology, 2022, Volume: 36, Issue:4 Topics: Animals; Atorvastatin; Benzhydryl Compounds; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Liraglutide; Male; Pyrroles; Rats; Thyrotropin	2022
Antidiabetic Effect of BioMed research international, 2022, Volume: 2022 Topics: Adipocytes; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Down-Regulation; Gene Expression; Glucose; Hypoglycemic Agents; Inflammation; Lipoproteins, LDL; Momordica charantia; Phenylpropionates; Plant Extracts; Pyrroles; Tamarindus	2022
Inhibition of JAK-STAT and NF-κB signalling systems could be a novel therapeutic target against insulin resistance and type 2 diabetes. Life sciences, 2019, Dec-15, Volume: 239 Topics: Animals; Aspirin; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Interleukin-6; Janus Kinases; Male; NF-kappa B; Piperidines; Pyrimidines; Pyrroles; Rats; Rats, Wistar; Serum Amyloid A Protein; Signal Transduction; STAT Transcription Factors; Tumor Necrosis Factor-alpha	2019
Discovery of an Orally Active and Long-Acting DPP-IV Inhibitor through Property-Based Optimization with an in Silico Biotransformation Prediction Tool. ChemMedChem, 2020, 08-19, Volume: 15, Issue:16 Topics: Administration, Oral; Biotransformation; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Humans; Hypoglycemic Agents; Molecular Structure; Pyrimidines; Pyrroles; Structure-Activity Relationship	2020
[Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2020, Volume: 155, Issue:5 Topics: Aged; Animals; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Humans; Hypertension; Japan; Middle Aged; Mineralocorticoid Receptor Antagonists; Pyrroles; Rats; Sulfones; Tablets; Treatment Outcome	2020
Pyrrolo[1,2-a]quinoxalines: Insulin Mimetics that Exhibit Potent and Selective Inhibition against Protein Tyrosine Phosphatase 1B. ChemMedChem, 2020, 10-05, Volume: 15, Issue:19 Topics: Animals; Cell Differentiation; Cell Line; Cell Survival; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glucose; Hep G2 Cells; Humans; Insulin; Mice; Models, Molecular; Molecular Structure; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Pyrroles; Quinoxalines; Structure-Activity Relationship	2020
SIS3, a good candidate for the reverse of type 2 diabetes mellitus in mice. Fundamental & clinical pharmacology, 2021, Volume: 35, Issue:2 Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Glucose Tolerance Test; Isoquinolines; Male; Mice; Mice, Inbred C57BL; Pyridines; Pyrroles	2021
Mineralocorticoid Receptor Antagonists for Diabetic Kidney Disease. Clinical journal of the American Society of Nephrology : CJASN, 2020, 12-07, Volume: 15, Issue:12 Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Mineralocorticoid Receptor Antagonists; Pyrroles; Sulfones	2020
Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. Scientific reports, 2020, 12-03, Volume: 10, Issue:1 Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Humans; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Prospective Studies; Pyrroles; Regression Analysis	2020
Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes. Bioorganic & medicinal chemistry letters, 2018, 03-01, Volume: 28, Issue:5 Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Discovery; Humans; Hypoglycemic Agents; Mice; Molecular Structure; Pyrroles; Receptors, G-Protein-Coupled; Structure-Activity Relationship	2018
MC1568 improves insulin secretion in islets from type 2 diabetes patients and rescues β-cell dysfunction caused by Hdac7 upregulation. Acta diabetologica, 2018, Volume: 55, Issue:12 Topics: Adult; Aged; Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Insulin; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Male; Middle Aged; Pyrroles; Rats; Up-Regulation	2018
Plaque stabilization by intensive LDL-cholesterol lowering therapy with atorvastatin is delayed in type 2 diabetic patients with coronary artery disease-Serial angioscopic and intravascular ultrasound analysis. Journal of cardiology, 2013, Volume: 61, Issue:6 Topics: Aged; Angioscopy; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Risk Factors; Time Factors; Ultrasonography, Interventional	2013
Statin treatment and diabetes. Journal of the American College of Cardiology, 2013, May-07, Volume: 61, Issue:18 Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin	2013
How to balance cardiometabolic benefits and risks of statins. Journal of the American College of Cardiology, 2013, May-07, Volume: 61, Issue:18 Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin	2013
Reply: To PMID 23219296. Journal of the American College of Cardiology, 2013, May-07, Volume: 61, Issue:18 Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin	2013
Standards of statin usage in Poland in high-risk patients: 3ST-POL study results. Kardiologia polska, 2013, Volume: 71, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticholesteremic Agents; Atorvastatin; Cardiology; Cardiovascular Diseases; Cohort Studies; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Utilization; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Outpatients; Patient Compliance; Poland; Population Surveillance; Primary Health Care; Pyrroles; Simvastatin; Surveys and Questionnaires; Treatment Failure	2013
Risk of incident diabetes among patients treated with statins: population based study. BMJ (Clinical research ed.), 2013, May-23, Volume: 346 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2013
ACP Journal Club. Meta-analysis: Atorvastatin reduces CV events and increases new-onset diabetes in patients with coronary disease. Annals of internal medicine, 2013, Jul-16, Volume: 159, Issue:2 Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin	2013
The first approved agent in the Glitazar's Class: Saroglitazar. Current drug targets, 2014, Volume: 15, Issue:2 Topics: Administration, Oral; Adult; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypoglycemic Agents; India; Lipid Metabolism; Middle Aged; Phenylpropionates; Pyrroles; Young Adult	2014
Sunitinib-induced severe hypoglycemia in a diabetic patient. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2014, Volume: 20, Issue:6 Topics: Antineoplastic Agents; Blood Glucose; Carcinoma, Renal Cell; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Severity of Illness Index; Sunitinib	2014
Effects of atorvastatin and insulin in vascular dysfunction associated with type 2 diabetes. Physiological research, 2014, Volume: 63, Issue:2 Topics: Animals; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Heptanoic Acids; Hypoglycemic Agents; Insulin; Male; Pyrroles; Rats; Treatment Outcome	2014
Mystery case: a 63-year-old man with progressive proximal pain and weakness. Neurology, 2014, Jan-28, Volume: 82, Issue:4 Topics: Atorvastatin; Blood Sedimentation; C-Reactive Protein; Creatine Kinase; Diabetes Mellitus, Type 2; Disease Progression; Electromyography; Fatigue; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscle Weakness; Neuromuscular Junction Diseases; Pain; Pyrroles; Shoulder Pain; Tomography, X-Ray Computed	2014
Atorvastatin prevents type 2 diabetes mellitus--an experimental study. European journal of pharmacology, 2014, Apr-05, Volume: 728 Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Lipid Metabolism; Male; Pyrroles; Rats; Rats, Wistar; Triglycerides	2014
Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors. European journal of medicinal chemistry, 2014, Mar-21, Volume: 75 Topics: Animals; Cell Line; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Mice; Mice, Inbred ICR; Models, Molecular; Nitriles; Pyrroles; Structure-Activity Relationship	2014
LDL cholesterol variability in patients with Type 2 diabetes taking atorvastatin and simvastatin: a comparison of two formulae for LDL-C estimation. Annals of clinical biochemistry, 2015, Volume: 52, Issue:Pt 1 Topics: Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Drug Monitoring; Half-Life; Heptanoic Acids; Humans; Hypolipidemic Agents; Immunoassay; Prospective Studies; Pyrroles; Simvastatin; Triglycerides	2015
The effect of leptin promoter and leptin receptor gene polymorphisms on lipid profile among the diabetic population: modulations by atorvastatin treatment and environmental factors. Journal of endocrinological investigation, 2014, Volume: 37, Issue:9 Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Gene-Environment Interaction; Genotype; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leptin; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Receptors, Leptin; Sex Factors; Triglycerides	2014
Statins on trial. Pfizer faces clot of lawsuits that claim Lipitor caused women's diabetes. Modern healthcare, 2014, May-19, Volume: 44, Issue:20 Topics: Atorvastatin; Diabetes Mellitus, Type 2; Drug Industry; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Sex Factors; United States	2014
[Impacts of atorvastatin on blood lipids and arterial media thickness in new-onset type 2 diabetes patients]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi, 2014, Volume: 35, Issue:6 Topics: Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Pyrroles; Tunica Media	2014
Vascular injury in diabetic db/db mice is ameliorated by atorvastatin: role of Rac1/2-sensitive Nox-dependent pathways. Clinical science (London, England : 1979), 2015, Volume: 128, Issue:7 Topics: Acetylcholine; Animals; Arteries; Atorvastatin; Blotting, Western; Diabetes Mellitus, Type 2; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; In Vitro Techniques; Insulin; Lipids; Male; Mice, Mutant Strains; Mitogen-Activated Protein Kinases; NADPH Oxidases; Phosphorylation; Pyrroles; rac GTP-Binding Proteins; rac1 GTP-Binding Protein; RAC2 GTP-Binding Protein; Reactive Oxygen Species; Receptors, Leptin; Signal Transduction; Thiobarbituric Acid Reactive Substances; Vasodilation; Vasodilator Agents	2015
Sunitinib and improved diabetes control. BMJ case reports, 2014, Dec-24, Volume: 2014 Topics: Antineoplastic Agents; Blood Glucose; Carcinoma, Renal Cell; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Indoles; Insulin; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Sunitinib	2014
Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes. Scientific reports, 2015, Jan-09, Volume: 5 Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Male; Middle Aged; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Treatment Outcome; Triglycerides	2015
Effects of atorvastatin and rosuvastatin on renal function in patients with type 2 diabetes mellitus. The American journal of cardiology, 2015, Mar-01, Volume: 115, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Asian People; Atorvastatin; China; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Taiwan	2015
The marketing of unproven drugs for diabetes and dyslipidaemia in India. The lancet. Diabetes & endocrinology, 2015, Volume: 3, Issue:10 Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxychloroquine; Hypoglycemic Agents; India; Marketing; Phenylpropionates; Pyrroles	2015
Indian endocrinologists start debate on diabetes drug. BMJ (Clinical research ed.), 2015, Sep-29, Volume: 351 Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxychloroquine; Marketing; Phenylpropionates; Pyrroles	2015
Drug approvals in India. The lancet. Diabetes & endocrinology, 2016, Volume: 4, Issue:1 Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxychloroquine; Marketing; Phenylpropionates; Pyrroles	2016
Drug approvals in India. The lancet. Diabetes & endocrinology, 2016, Volume: 4, Issue:1 Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxychloroquine; Marketing; Phenylpropionates; Pyrroles	2016
Drug approvals in India - Authors' reply. The lancet. Diabetes & endocrinology, 2016, Volume: 4, Issue:1 Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxychloroquine; Marketing; Phenylpropionates; Pyrroles	2016
Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes. Bioorganic & medicinal chemistry, 2016, May-01, Volume: 24, Issue:9 Topics: Administration, Oral; Animals; Biological Availability; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Discovery; Glucose Tolerance Test; Male; Mice; Mice, Inbred ICR; Molecular Docking Simulation; Pyrroles; Receptors, G-Protein-Coupled; Structure-Activity Relationship	2016
Circulating Neutrophil Extracellular Trap Levels in Well-Controlled Type 2 Diabetes and Pathway Involved in Their Formation Induced by High-Dose Glucose. Pathobiology : journal of immunopathology, molecular and cellular biology, 2016, Volume: 83, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; DNA; Dose-Response Relationship, Drug; Extracellular Traps; Glucose; Humans; Hypoglycemic Agents; Middle Aged; Neutrophils; Peroxidase; Polymers; Pyrazines; Pyrroles; Quinazolines; Risk Factors; Spiro Compounds; Time Factors	2016
American Diabetes Association - 76th Scientific Sessions (June 10-14, 2016 - New Orleans, Louisiana, USA). Drugs of today (Barcelona, Spain : 1998), 2016, Volume: 52, Issue:6 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Phenylpropionates; Pyrroles	2016
Thioredoxin interacting protein mediates lipid-induced impairment of glucose uptake in skeletal muscle. Biochemical and biophysical research communications, 2016, Oct-28, Volume: 479, Issue:4 Topics: AMP-Activated Protein Kinases; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Biological Transport, Active; Carrier Proteins; Cell Line; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Fenofibrate; Glucose; Glucose Transporter Type 4; Insulin Resistance; Mice; Muscle Fibers, Skeletal; Nuclear Proteins; Palmitic Acid; Phenylpropionates; Pyrroles; Reactive Oxygen Species; Sirtuin 1; Thioredoxins; Transcription Factors	2016
A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia. Naunyn-Schmiedeberg's archives of pharmacology, 2009, Volume: 379, Issue:3 Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Drug Therapy, Combination; Fatty Liver; Heptanoic Acids; Hyperlipidemias; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Resistance; Lipids; Oxidative Stress; Pyrroles; Rats; Rats, Inbred Strains	2009
Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting. Diabetic medicine : a journal of the British Diabetic Association, 2008, Volume: 25, Issue:8 Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Lipid Metabolism; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome	2008
Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. Journal of atherosclerosis and thrombosis, 2008, Volume: 15, Issue:5 Topics: Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Drug Evaluation; Glucose Intolerance; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Retrospective Studies	2008
Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes. Diabetes care, 2009, Volume: 32, Issue:4 Topics: Adult; Aged; Atorvastatin; Biological Availability; Diabetes Mellitus, Type 2; Estradiol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Sex Hormone-Binding Globulin; Simvastatin; Testosterone	2009
Targeting targets for LDL-lowering therapy: lessons from the Collaborative Atorvastatin Diabetes Study (CARDS). Clinical chemistry, 2009, Volume: 55, Issue:3 Topics: Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Multicenter Studies as Topic; Pyrroles	2009
Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats. The Journal of pharmacology and experimental therapeutics, 2009, Volume: 330, Issue:2 Topics: Acute Disease; Animals; Atorvastatin; Brain Ischemia; Cerebral Hemorrhage; Diabetes Mellitus, Type 2; Drug Administration Schedule; Heptanoic Acids; Male; Pyrroles; Rats; Rats, Wistar; Time Factors	2009
Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein. Expert opinion on therapeutic targets, 2009, Volume: 13, Issue:7 Topics: Aged; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Triglycerides	2009
Unexpected and abnormally low HDL cholesterol levels on combination hypolipidemic therapy. The Journal of the Association of Physicians of India, 2009, Volume: 57 Topics: Atorvastatin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrroles	2009
Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis, 2010, Volume: 209, Issue:1 Topics: Asian People; Atorvastatin; Cell Line; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Receptor for Advanced Glycation End Products; Receptors, Immunologic	2010
2-(3,4-Dihydro-2H-pyrrolium-1-yl)-3oxoindan-1-olate (DHPO), a novel, synthetic small molecule that alleviates insulin resistance and lipid abnormalities. Biochemical pharmacology, 2010, Feb-15, Volume: 79, Issue:4 Topics: Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Drugs, Investigational; Hypoglycemic Agents; Indans; Insulin Resistance; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Mice, Transgenic; Pyrroles	2010
Comparison of the effects of simvastatin versus atorvastatin on oxidative stress in patients with type 2 diabetes mellitus. Journal of cardiovascular pharmacology, 2010, Volume: 55, Issue:1 Topics: Aged; Atorvastatin; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin	2010
Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus. Journal of clinical hypertension (Greenwich, Conn.), 2009, Volume: 11, Issue:10 Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Atorvastatin; Black or African American; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome	2009
Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population. Clinical drug investigation, 2010, Volume: 30, Issue:2 Topics: Aged; Atorvastatin; Belgium; Cardiovascular Diseases; Cholesterol, HDL; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drugs, Generic; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insurance, Health, Reimbursement; Male; Markov Chains; Middle Aged; Models, Economic; Models, Statistical; Pyrroles; Quality-Adjusted Life Years; Triglycerides	2010
Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes. Journal of atherosclerosis and thrombosis, 2010, Jun-30, Volume: 17, Issue:6 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; CD36 Antigens; Cells, Cultured; Diabetes Mellitus, Type 2; Down-Regulation; Female; Heptanoic Acids; Humans; Inflammation; Male; Middle Aged; Monocytes; NF-kappaB-Inducing Kinase; Protein Serine-Threonine Kinases; Pyrroles; Tumor Necrosis Factor-alpha	2010
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010, Volume: 10, Issue:2 Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2010
Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes. Clinical journal of the American Society of Nephrology : CJASN, 2010, Volume: 5, Issue:5 Topics: Atorvastatin; Cardiovascular Diseases; Computer Simulation; Databases as Topic; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; United States	2010
Charting new territory by simulated modeling of a clinical trial. Clinical journal of the American Society of Nephrology : CJASN, 2010, Volume: 5, Issue:5 Topics: Atorvastatin; Cardiovascular Diseases; Computer Simulation; Databases as Topic; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome	2010
Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement? Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:6 Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Half-Life; Heptanoic Acids; Humans; Hypercholesterolemia; Lipid Metabolism; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome	2010
Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes. Annals of clinical biochemistry, 2011, Volume: 48, Issue:Pt 1 Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2011
Atorvastatin prevents ischemic limb loss in type 2 diabetes: role of p53. Journal of atherosclerosis and thrombosis, 2011, Volume: 18, Issue:3 Topics: Animals; Atorvastatin; Blotting, Western; Cells, Cultured; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Extremities; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Ischemia; Male; Mice; Myoblasts; Peripheral Arterial Disease; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Pyrroles; Tumor Suppressor Protein p53; Ubiquitin; Wound Healing	2011
Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. Diabetes/metabolism research and reviews, 2011, Volume: 27, Issue:1 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; C-Reactive Protein; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Liver; Heptanoic Acids; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Interleukin-6; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Pyrroles; Rats; Rats, Inbred Strains; Tumor Necrosis Factor-alpha	2011
Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia. Endocrine journal, 2011, Volume: 58, Issue:3 Topics: Aged; Atorvastatin; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Epichlorohydrin; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Hypoglycemic Agents; Imidazoles; Lipids; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyrroles; Quinolines; Resins, Synthetic; Retrospective Studies; Treatment Outcome	2011
Nitric oxide-donating statin improves multiple functions of circulating angiogenic cells. British journal of pharmacology, 2011, Volume: 164, Issue:2b Topics: Aged; Anticholesteremic Agents; Apoptosis; Benzoates; Cardiovascular Agents; Cardiovascular Diseases; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellular Senescence; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Leukocytes, Mononuclear; Male; Middle Aged; Neovascularization, Physiologic; Nitrates; Nitric Oxide Donors; Nitric Oxide Synthase Type III; Ornithine; Proto-Oncogene Proteins c-akt; Pyrroles; Stem Cells	2011
Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus--an observational study from the Swedish National Diabetes Register. PloS one, 2011, Apr-29, Volume: 6, Issue:4 Topics: Adolescent; Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Statistical; Pyrimidines; Pyrroles; Registries; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Sweden; Treatment Outcome	2011
The effects of triple vs. dual and monotherapy with rosiglitazone, glimepiride, and atorvastatin on lipid profile and glycemic control in type 2 diabetes mellitus rats. Fundamental & clinical pharmacology, 2012, Volume: 26, Issue:5 Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Female; Glycated Hemoglobin; Heptanoic Acids; Hypolipidemic Agents; Lipids; Male; Pyrroles; Rats; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2012
Drug repurposing for vascular protection after acute ischemic stroke. Acta neurochirurgica. Supplement, 2011, Volume: 111 Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Brain Infarction; Diabetes Mellitus, Type 2; Disease Models, Animal; Enalapril; Enzyme-Linked Immunosorbent Assay; Functional Laterality; Hemoglobins; Hemorrhage; Heptanoic Acids; Male; Matrix Metalloproteinase 9; Pyrroles; Rats; Rats, Inbred SHR; Rats, Wistar; Reperfusion; Stroke; Tetrazoles; Vascular System Injuries	2011
Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes. Acta diabetologica, 2012, Volume: 49, Issue:4 Topics: Aged; Apelin; Atorvastatin; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cytokines; Diabetes Mellitus, Type 2; Female; Ghrelin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Pyrroles	2012
Beneficial effect of atorvastatin on renal function in patients with type 2 diabetes. The Journal of international medical research, 2011, Volume: 39, Issue:4 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glycated Hemoglobin; Glycemic Index; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Function Tests; Male; Middle Aged; Prognosis; Prospective Studies; Pyrroles; Retrospective Studies; Risk Factors; Triglycerides	2011
Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). Journal of lipid research, 2012, Volume: 53, Issue:5 Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Genome-Wide Association Study; Genotype; Glucosyltransferases; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Placebo Effect; Polymorphism, Single Nucleotide; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Lysophosphatidic Acid; Treatment Outcome	2012
Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-pres Geriatrics & gerontology international, 2012, Volume: 12 Suppl 1 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Proportional Hazards Models; Pyrroles	2012
Statins and glycaemic control--a cause for concern? Diabetic medicine : a journal of the British Diabetic Association, 2012, Volume: 29, Issue:5 Topics: Atorvastatin; Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides	2012
Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats. Fundamental & clinical pharmacology, 2013, Volume: 27, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Therapy, Combination; Heptanoic Acids; Hypercholesterolemia; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Losartan; Male; Obesity; Pioglitazone; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Thiazolidinediones; Tumor Necrosis Factor-alpha	2013
FOXO1 impairs whereas statin protects endothelial function in diabetes through reciprocal regulation of Kruppel-like factor 2. Cardiovascular research, 2013, Jan-01, Volume: 97, Issue:1 Topics: Animals; Atorvastatin; Base Sequence; Binding Sites; Blood Glucose; Cells, Cultured; Chromatin Immunoprecipitation; Cytoprotection; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kruppel-Like Transcription Factors; Male; Mevalonic Acid; Molecular Sequence Data; Nerve Tissue Proteins; Nitric Oxide Synthase Type III; Phosphorylation; Promoter Regions, Genetic; Pyrroles; Rats; Rats, Inbred OLETF; RNA Interference; Time Factors; Transfection; Vasodilation; Vasodilator Agents	2013
The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members. Basic & clinical pharmacology & toxicology, 2013, Volume: 112, Issue:4 Topics: Administration, Oral; Atorvastatin; Biological Transport; Diabetes Mellitus, Type 2; Drug Interactions; HEK293 Cells; Heptanoic Acids; Humans; Hypoglycemic Agents; Liver; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfobromophthalein	2013
Protein kinase C-β contributes to impaired endothelial insulin signaling in humans with diabetes mellitus. Circulation, 2013, Jan-01, Volume: 127, Issue:1 Topics: Adult; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelial Cells; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mesylates; Middle Aged; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Protein Kinase C; Protein Kinase C beta; Pyrroles; Signal Transduction	2013
Atorvastatin ameliorates podocyte injury in patients with type 2 diabetes complicated with dyslipidemia. Diabetes research and clinical practice, 2013, Volume: 100, Issue:1 Topics: Aged; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dyslipidemias; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxidative Stress; Podocytes; Pyrroles	2013
The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:8 Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Pyrroles; Simvastatin; Treatment Outcome; Vitamin D	2013
Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2002, Volume: 12, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Longitudinal Studies; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; Triglycerides	2002
Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. Metabolism: clinical and experimental, 2003, Volume: 52, Issue:1 Topics: Actins; Aging; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Insulin; Male; Mice; Mice, Inbred C57BL; Peptide Fragments; Proglucagon; Protease Inhibitors; Protein Precursors; Pyrroles; Valine	2003
Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes. The Journal of pharmacology and experimental therapeutics, 2003, Volume: 306, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Kinetics; Lipid Metabolism; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Pyrroles	2003
Increased urinary levels of pentosidine, pyrraline and acrolein adduct in type 2 diabetes. Endocrine journal, 2003, Volume: 50, Issue:1 Topics: Acrolein; Adult; Arginine; Blood Pressure; Diabetes Mellitus, Type 2; Female; Humans; Hyperglycemia; Lysine; Male; Middle Aged; Norleucine; Pyrroles; Smoking	2003
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. Diabetes care, 2003, Volume: 26, Issue:6 Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; United States	2003
[Comparative study of lipid lowering effect and influence on platelet aggregation of atorvastatin and simvastatin in patients ischemic heart disease with type II diabetes and combined hyperlipidemia]. Kardiologiia, 2003, Volume: 43, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation; Pyrroles; Simvastatin	2003
Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment. European journal of clinical investigation, 2003, Volume: 33, Issue:11 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Feces; Heptanoic Acids; Humans; Hypercholesterolemia; Intestinal Absorption; Lipids; Lipoproteins; Liver; Male; Middle Aged; Phytosterols; Pyrroles; Squalene	2003
Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis. Nephron. Clinical practice, 2003, Volume: 95, Issue:4 Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Homocysteine; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Lipid Metabolism; Lipids; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Renal Dialysis; Risk Factors	2003
Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation. Circulation research, 2004, Apr-16, Volume: 94, Issue:7 Topics: Acetylcysteine; Adult; Aged; Anti-Infective Agents; Antioxidants; Arteriosclerosis; Cells, Cultured; Curcumin; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Flavonoids; Foam Cells; Gene Expression Regulation; Glucose; Glycation End Products, Advanced; Humans; Hyperglycemia; Macrophages; Male; MAP Kinase Signaling System; Mesylates; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; NF-kappa B; Nitriles; Phosphorylation; Protein Kinase C; Protein Kinase C beta; Protein Processing, Post-Translational; Pyrroles; Receptors, LDL; RNA, Messenger; Signal Transduction; Sulfones; Transcription Factor AP-1; Tumor Necrosis Factor-alpha	2004
Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3. Journal of medicinal chemistry, 2004, Jul-29, Volume: 47, Issue:16 Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Imidazoles; Pyridines; Pyrroles; Rats; Rats, Zucker	2004
The lipid-regulating effects of atorvastatin on type 2 elder diabetes patients with hyperlipidemia. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2004, Volume: 24, Issue:2 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Triglycerides	2004
Dissociation between urinary pyrraline and pentosidine concentrations in diabetic patients with advanced nephropathy. The Journal of laboratory and clinical medicine, 2004, Volume: 144, Issue:2 Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Arginine; beta 2-Microglobulin; Biomarkers; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glycated Hemoglobin; Humans; Lysine; Pyrroles; Reference Values; Regression Analysis	2004
Study suggests statins for diabetics with healthy LDL cholesterol levels. Report on medical guidelines & outcomes research, 2004, Sep-17, Volume: 15, Issue:18 Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Middle Aged; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Triglycerides	2004
Effect of atorvastatin on non-cholesterol sterols in patients with type 2 diabetes mellitus and cardiovascular disease. Pharmacological research, 2005, Volume: 51, Issue:1 Topics: Aged; Analysis of Variance; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Statistics, Nonparametric; Sterols	2005
[Atorvastatin lowers C-reactive protein in dislipemic patients with type 2 diabetes mellitus]. Medicina clinica, 2004, Oct-23, Volume: 123, Issue:14 Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles	2004
[CARDS confirms usefulness of LDL lowering in type 2 diabetics]. Praxis, 2004, Oct-27, Volume: 93, Issue:44 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Placebos; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Time Factors	2004
[The CARDS Study: cardiovascular primary prevention in diabetes patients using Atorvastin]. Der Internist, 2005, Volume: 46, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome	2005
CARDS on the table: should everybody with type 2 diabetes take a statin? Current medical research and opinion, 2005, Volume: 21, Issue:3 Topics: Atorvastatin; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors; Vascular Diseases	2005
Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension. American journal of hypertension, 2005, Volume: 18, Issue:4 Pt 1 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunoenzyme Techniques; Kidney; Kidney Glomerulus; Linear Models; Microscopy, Electron; Obesity; Pyrroles; Quinapril; Rats; Rats, Zucker; Staining and Labeling; Tetrahydroisoquinolines	2005
Effects of atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice. Journal of atherosclerosis and thrombosis, 2005, Volume: 12, Issue:2 Topics: Animals; Arteriosclerosis; Atorvastatin; Biomarkers; Blood Glucose; Blotting, Northern; CCAAT-Enhancer-Binding Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Gene Expression Regulation, Enzymologic; Glucose Tolerance Test; Glucose-6-Phosphatase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Lipids; Male; Mice; Mice, Inbred Strains; Pyrroles; RNA, Messenger; Sterol Regulatory Element Binding Protein 1; Transcription Factors	2005
Atorvastatin induces insulin sensitization in Zucker lean and fatty rats. Atherosclerosis, 2006, Volume: 184, Issue:2 Topics: Adipose Tissue; Animals; Atorvastatin; Blotting, Western; Body Weight; Diabetes Mellitus, Type 2; Follow-Up Studies; Glucose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Muscle, Skeletal; Phosphorylation; Pyrroles; Rats; Rats, Zucker	2006
Acute onset and worsening of diabetes concurrent with administration of statins. Endocrine journal, 2005, Volume: 52, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles	2005
Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes. The Journal of pharmacology and experimental therapeutics, 2005, Volume: 315, Issue:1 Topics: Aged; Apolipoprotein A-I; Apolipoproteins E; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins, HDL; Lipoproteins, VLDL; Male; Middle Aged; Pyrroles	2005
Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. Journal of atherosclerosis and thrombosis, 2005, Volume: 12, Issue:4 Topics: Aged; Arteries; Atorvastatin; Blood Flow Velocity; Blood Pressure; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leg; Male; Middle Aged; Prospective Studies; Pyrroles	2005
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): response to Server et al. Diabetes care, 2005, Volume: 28, Issue:10 Topics: Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic	2005
Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis. The New England journal of medicine, 2005, Oct-27, Volume: 353, Issue:17 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis; Treatment Failure	2005
Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis. The New England journal of medicine, 2005, Oct-27, Volume: 353, Issue:17 Topics: Atorvastatin; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis; Treatment Failure	2005
Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis. The New England journal of medicine, 2005, Oct-27, Volume: 353, Issue:17 Topics: Atorvastatin; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis; Risk Factors; Stroke	2005
Statins for high-risk patients without heart disease or high cholesterol. The Medical letter on drugs and therapeutics, 2006, Jan-02, Volume: 48, Issue:1225 Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pravastatin; Pyrroles; Simvastatin; Stroke	2006
Reduction in cardiovascular events with atorvastatin in type 2 diabetes. Current atherosclerosis reports, 2006, Volume: 8, Issue:1 Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke	2006
Medication costs as a primary cause of nonadherence in the elderly. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2006, Volume: 21, Issue:2 Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Prescriptions; Drugs, Generic; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Metformin; Metoprolol; Patient Compliance; Pharmacists; Pyrroles; Self Administration	2006
Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia, 2006, Volume: 49, Issue:8 Topics: 3T3 Cells; Adipocytes; Animals; Atorvastatin; Biological Transport; Blood Glucose; Cell Differentiation; Cellular Senescence; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Glucose Transporter Type 4; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Middle Aged; Obesity; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction	2006
Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus. Journal of atherosclerosis and thrombosis, 2006, Volume: 13, Issue:2 Topics: Aged; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucose Tolerance Test; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoglycemic Agents; Male; Middle Aged; Pravastatin; Pyrroles; Retrospective Studies	2006
[Cost-effectiveness analysis of the use of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic model of the CARDS study]. Anales de medicina interna (Madrid, Spain : 1984), 2006, Volume: 23, Issue:5 Topics: Adult; Aged; Atorvastatin; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrroles; Retrospective Studies	2006
High-dose statins for diabetes. Health news (Waltham, Mass.), 2006, Volume: 12, Issue:8 Topics: Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles	2006
Does statin therapy improve cardiovascular outcomes in patients with type 2 diabetes receiving hemodialysis? Nature clinical practice. Nephrology, 2006, Volume: 2, Issue:2 Topics: Atorvastatin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis	2006
Effect of atorvastatin on soluble CD14, CD40 Ligand, sE- and sP-selectins and MCP-1 in patients with type 2 diabetes mellitus: relationship to cholesterol turnover. Pharmacological research, 2006, Volume: 54, Issue:6 Topics: Atorvastatin; CD40 Antigens; Chemokine CCL2; Cholesterol; Diabetes Mellitus, Type 2; E-Selectin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligands; Lipid Metabolism; Lipopolysaccharide Receptors; Male; Middle Aged; P-Selectin; Pyrroles	2006
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Diabetes care, 2006, Volume: 29, Issue:11 Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Pyrroles	2006
Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circulation journal : official journal of the Japanese Circulation Society, 2007, Volume: 71, Issue:1 Topics: Adiponectin; Adipose Tissue; Animals; Anticholesteremic Agents; Atorvastatin; Chemokine CCL2; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Glucose; Heptanoic Acids; Hypertriglyceridemia; Insulin Resistance; Leptin; Myocardium; Nitric Oxide; Nitric Oxide Synthase Type III; Pravastatin; Pyrroles; Rats; Rats, Long-Evans; Rats, Mutant Strains; RNA, Messenger; Transforming Growth Factor beta1; Ventricular Dysfunction, Left	2007
Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia, 2007, Volume: 50, Issue:4 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Models, Economic; Primary Prevention; Pyrroles; Quality-Adjusted Life Years	2007
Did a flawed study design affect the results of the VYTAL study? Mayo Clinic proceedings, 2007, Volume: 82, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Diabetes Mellitus, Type 2; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Multicenter Studies as Topic; Pyrroles; Random Allocation; Research Design; Simvastatin	2007
An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes. PharmacoEconomics, 2008, Volume: 26, Issue:4 Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Economic; Pyrroles; Quality-Adjusted Life Years	2008
Short term effects of atorvastatin on endothelial functions and oxidized LDL levels in patients with type 2 diabetes. Endocrine journal, 2008, Volume: 55, Issue:5 Topics: Atherosclerosis; Atorvastatin; Biomarkers; Brachial Artery; Carotid Arteries; Cholesterol, LDL; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Inflammation; Lipids; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Tunica Intima	2008
Normalization of insulin secretion by a selective alpha 2-adrenoceptor antagonist restores GLUT-4 glucose transporter expression in adipose tissue of type II diabetic rats. Endocrinology, 1996, Volume: 137, Issue:5 Topics: Adipose Tissue; Adipose Tissue, Brown; Adrenergic alpha-Antagonists; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gene Expression; Glucose Tolerance Test; Glucose Transporter Type 4; Indoles; Insulin; Insulin Secretion; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Myocardium; Pyrroles; Rats; Rats, Wistar; RNA, Messenger	1996
Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. The Journal of clinical investigation, 1997, Dec-15, Volume: 100, Issue:12 Topics: Adolescent; Adult; Aged; Animals; Antibodies; Arginine; Collagen; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glycation End Products, Advanced; Humans; Immunoenzyme Techniques; Kidney Glomerulus; Lipid Peroxidation; Lysine; Male; Malondialdehyde; Mice; Middle Aged; Nephrotic Syndrome; Norleucine; Pyrroles; Rabbits	1997
Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology, 1997, Volume: 50, Issue:6 Topics: Adult; Aged; Arginine; Blotting, Western; Chromatography, High Pressure Liquid; Cross-Linking Reagents; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Electron Probe Microanalysis; Endothelium; Enzyme Induction; Erectile Dysfunction; Glycation End Products, Advanced; Humans; Immunohistochemistry; Lysine; Male; Middle Aged; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Norleucine; Penis; Pyrroles	1997
Substituted tetrahydropyrrolo[2,1-b]oxazol-5(6H)-ones and tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones as hypoglycemic agents. Journal of medicinal chemistry, 1998, Nov-05, Volume: 41, Issue:23 Topics: Animals; Cell Line; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Glucose; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Muscles; Oxazoles; Pyrroles; Rats; Structure-Activity Relationship; Thiazoles	1998
Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney international. Supplement, 1999, Volume: 71 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Proportional Hazards Models; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Research Design; Treatment Outcome	1999
Status report of lipid-lowering trials in diabetes. Current opinion in lipidology, 2000, Volume: 11, Issue:6 Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Pyrroles; Risk Factors	2000
Advanced glycation end products in human optic nerve head. The British journal of ophthalmology, 2001, Volume: 85, Issue:1 Topics: Aged; Diabetes Mellitus, Type 2; Ethmoid Bone; Female; Glycosylation; Humans; Immunoenzyme Techniques; Male; Middle Aged; Norleucine; Optic Disk; Pia Mater; Pyrroles; Retinal Vessels; Sclera	2001
A convenient synthesis of the novel hypoglycemic agent SDZ PGU 693. The Journal of organic chemistry, 2001, Jul-13, Volume: 66, Issue:14 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Oxazoles; Pyrroles	2001
Atorvastatin versus micronized fenofibrate in the treatment of patients with mixed hyperlipoproteinemia. The American journal of cardiology, 2001, Jul-15, Volume: 88, Issue:2 Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Fenofibrate; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Pyrroles	2001
Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. Metabolism: clinical and experimental, 2001, Volume: 50, Issue:8 Topics: Atorvastatin; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Lipoproteins, LDL; Male; Middle Aged; Pyrroles	2001
Insulin resistance syndrome and type 2 diabetes mellitus. The American journal of cardiology, 2001, Oct-11, Volume: 88, Issue:7B Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Metabolic Syndrome; Pyrroles; Risk Factors; Survival Rate	2001
Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes. Arteriosclerosis, thrombosis, and vascular biology, 2002, May-01, Volume: 22, Issue:5 Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Drug Administration Schedule; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Microcirculation; Middle Aged; Nitric Oxide; Nitroprusside; Plethysmography; Prospective Studies; Pyrroles; Serotonin; Vasodilation	2002